CASE WESTERN RESERVE UNIVERSITY

Report on Federal Awards in Accordance With OMB Circular A-133 for the Year Ended June 30, 2010

Entity Identification Number 1-341018992-A1

CASE WESTERN RESERVE UNIVERSITY

REPORT ON FEDERAL AWARDS IN ACCORDANCE WITH OMB CIRCULAR A-133

June 30, 2010

TABLE OF CONTENTS

PART I	FINANCIAL	<u>Pages</u>
	Report of Independent Auditors	1
	Financial Statements and Notes for the year ended June 30, 2010	2-26
	Schedule of Expenditures of Federal Awards for the year ended June 30, 2010	27-40
	Notes to Schedule of Expenditures of Federal Awards for the year ended June 30, 2010	41-42
PART II	REPORTS ON COMPLIANCE AND ON THE INTERNAL CONTROL STRUCTURE	
	Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	43
	Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control over Compliance in Accordance with OMB Circular A-133	44-45
PART III	SCHEDULE OF FINDINGS AND QUESTIONED COSTS	
	Summary of Auditor's Results	46
	Financial Statement Findings	47
	Federal Award Findings and Questioned Costs	48-50
	Summary of Prior Year Findings and Questioned Costs	51
	Management's Corrective Action Plan	52





Report of Independent Auditors

To the Board of Trustees, Case Western Reserve University:

In our opinion, the accompanying consolidated statement of financial position and the related consolidated statements of activities and of cash flows present fairly, in all material respects, the financial position of Case Western Reserve University and its affiliated entities (the "University") as of June 30, 2010, and the changes in their net assets and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the University's management. Our responsibility is to express an opinion on these financial statements based on our audit. The prior year summarized comparative information has been derived from the University's 2009 financial statements, and in our report dated October 10, 2009, we expressed an unqualified opinion on those financial statements. We conducted our audit of these statements in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In accordance with *Government Auditing Standards*, we have also issued our report dated October 13, 2010 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters for the year ended June 30, 2010. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* and should be considered in assessing the results of our audit.

Our audit was conducted for the purpose of forming an opinion on the basic consolidated financial statements taken as a whole. The accompanying Schedule of Expenditures of Federal Awards for the year ended June 30, 2010 is presented for purposes of additional analysis as required by U.S. Office of Management and Budget Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations,* and is not a required part of the basic consolidated financial statements. Such information has been subjected to the auditing procedures applied in the audit of the basic consolidated financial statements and, in our opinion, is fairly stated in all material respects, in relation to the basic consolidated financial statements taken as a whole.

October 13, 2010 Cleveland, Ohio

Pricewaterhouse Copers LAP

CASE WESTERN RESERVE UNIVERSITY Consolidated Statements of Financial Position June 30, 2010 and 2009

(in thousands of dollars)

	Ju	ne 30, 2010	Ju	ne 30, 2009
Assets				
Cash and cash equivalents	\$	65,294	\$	43,236
Accounts and loans receivable, net		95,945		107,282
Pledges receivable, net		52,662		51,348
Prepaid expenses and other assets		10,060		16,314
Investments		1,263,505		1,261,891
Funds held in trust by others		255,729		220,656
Property, plant, equipment and books, net		769,446		795,088
Total assets	\$	2,512,641	\$	2,495,815
Liabilities				
Accounts payable and accrued expenses	\$	57,148	\$	59,226
Deferred income and other liabilities		53,339		47,248
Annuities payable		42,299		40,167
Refundable advances		6,587		8,116
Accrued pension liability		31,902		25,562
Notes and bonds payable		579,298		589,216
Refundable federal student loans		16,910		16,431
Total liabilities		787,483		785,966
Net Assets				
Unrestricted		187,485		219,400
Temporarily restricted		733,784		719,744
Permanently restricted		803,889		770,705
Total net assets		1,725,158		1,709,849
Total liabilities and net assets	\$	2,512,641	\$	2,495,815

The accompanying notes are an integral part of the consolidated financial statements.

CASE WESTERN RESERVE UNIVERSITY

Consolidated Statement of Activities

For the Year Ended June 30, 2010

with summarized financial information for the year ended June 30, 2009 (in thousands of dollars)

	Unrestricted	Temporarily Restricted	Permanently Restricted	Year Ended June 30, 2010	Year Ended June 30, 2009
Operating revenues					
Student tuition and fees	\$ 293,124			\$ 293,124	\$ 279,765
Less: Student aid	(118,197)			(118,197)	(112,731)
	174,927			174,927	167,034
Investment returns distributed for operations	87,733	\$ 1,037	\$ 232	89,002	93,928
Grants and contracts	260,945			260,945	270,433
CCLCM grants and contracts	88,530			88,530	89,962
Gifts and pledges	8,022	16,862	29,743	54,627	52,492
State of Ohio appropriation	3,253			3,253	3,571
Facilities and administrative cost recovery	75,705			75,705	67,687
Organized activities	11,180			11,180	9,861
Other sources	29,351		-	29,351	39,354
Auxiliary services	45,517			45,517	46,278
Net assets released from restrictions	35,126	(33,970)	(1,156)	· -	-
Total operating revenues	820,289	(16,071)	28,819	833,037	840,600
Operating expenses					
Instructional	253,578			253,578	241,929
Sponsored research and training	258,420			258,420	258,873
Other sponsored projects	28,191			28,191	29,171
CCLCM research and training	88,530			88,530	89,962
Libraries	21,416			21,416	20,828
Student services	20,356			20,356	18,921
University services	88,583			88,583	83,653
Auxiliary services - students	45,729			45,729	48,668
Auxiliary services - others	13,052			13,052	10,422
Total operating expenses	817,855	-	-	817,855	802,427
Net operating activity	2,434	(16,071)	28,819	15,182	38,173
Nonoperating activities					
Investment returns, reduced by operating					
distribution above	(13,118)	(5,548)	(9,177)	(27,843)	(279,054)
Net appreciation (depreciation) in the fair					
market value of investments	1,011	19,008	17,324	37,343	(183,861)
Change in liabilities due under life-income					
agreements			(3,782)	(3,782)	3,249
Loss on disposal of plant assets	(162)			(162)	(5,554)
Pension plan changes other than periodic					
benefit costs	(2,317)			(2,317)	(36,980)
Other non-operating activity	(3,112)			(3,112)	
Reclassification of net assets	(16,651)	16,651		-	
Net nonoperating activity	(34,349)	30,111	4,365	127	(502,200)
(Decrease) increase in net assets	(31,915)	14,040	33,184	15,309	(464,027)
Beginning net assets	219,400	719,744	770,705	1,709,849	2,173,876
Ending net assets	\$ 187,485	\$ 733,784	\$ 803,889	\$ 1,725,158	\$ 1,709,849

The accompanying notes are an integral part of the consolidated financial statements.

CASE WESTERN RESERVE UNIVERSITY

Consolidated Statements of Cash Flows

For the Years Ended June 30, 2010 and 2009

(in thousands of dollars)

	ar Ended e 30, 2010	ear Ended ne 30, 2009
CASH FLOWS FROM OPERATING ACTIVITIES	 	
Change in net assets	\$ 15,309	\$ (464,027)
Adjustments to reconcile change in net assets to net		
cash used for operating activities:		
Depreciation	64,406	64,918
Amortization of bond issuance costs	98	83
Amortization of bond premiums	(710)	(676)
Net unrealized (appreciation) depreciation in the fair market		
value of investments	(37,343)	183,861
Realized (gains) losses on investments	(41,963)	111,018
Increase to annuities payable resulting from actuarial adjustments	6,130	1,590
Gifts of property and equipment	-	(125)
Receipt of contributed securities	(3,732)	(4,103)
Loss on disposal of plant assets	162	5,554
Contributions restricted for long-term investment	(27,028)	(21,591)
Decrease in accounts and loans receivable	12,927	12,783
Increase in pledges receivable	(740)	(7,650)
Decrease in allowance for doubtful accounts	(1,232)	(11,650)
Decrease in prepaid expenses and other assets	6,156	566
Decrease in prepaid pension assets	-	11,418
(Increase) decrease in funds held in trust by others	(35,073)	80,062
Decrease in accounts payable and accrued expenses	(2,078)	(6,265)
Increase in deferred income and other liabilities	6,092	8,644
(Decrease) increase in refundable advances	(1,529)	2,059
Increase in accrued pension liability	 6,340	 25,562
Net cash used for operating activities	(33,808)	(7,969)
CASH FLOWS FROM INVESTING ACTIVITIES		
Student loans collected	5,870	5,151
Student loans issued	(6,802)	(7,382)
Proceeds from the sale of investments	1,759,321	2,137,861
Purchase of investments	(1,677,897)	(2,083,251)
Proceeds from the sale of plant assets	217	270
Purchase of property, plant, equipment and books	(39,143)	(68,769)
Net cash provided by (used for) investing activities	 41,566	 (16,120)
CASH FLOWS FROM FINANCING ACTIVITIES	11,500	 (10,120)
CASH FLOWS FROM FRVANCING ACTIVITIES		
Increase in federal advances for student loans	478	278
Decrease in securities pledged under lending agreements	-	36,346
Decrease in payables under securities lending agreements	-	(37,655)
Contributions restricted for long-term investment	27,028	21,591
Proceeds from bond issues and long-term debt	2,361	23,100
Repayment of notes and bonds payable	(11,569)	(24,206)
Decrease to annuities payable resulting from payments	(4,963)	(5,693)
Increase to annuities payable resulting from new gifts	965	474
Net cash provided by financing activities	14,300	14,235
Net increase (decrease) in cash and cash equivalents	22,058	(9,854)
Cash and cash equivalents, beginning of year	 43,236	 53,090
Cash and cash equivalents, end of year	\$ 65,294	\$ 43,236
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES		
Construction in progress payments included in accounts payable	\$ 1,899	\$ 1,689

The accompanying notes are an integral part of the consolidated financial statements.

1. Basis of Presentation and Summary of Significant Accounting Policies and Terms

Basis of Presentation

Case Western Reserve University (the "University") is an Ohio not-for-profit corporation that operates a private research university in Cleveland, Ohio. The consolidated financial statements of the University as of June 30, 2010, and for the year then ended, have been prepared in accordance with accounting principles generally accepted in the United States of America. Accordingly, the accompanying consolidated financial statements have been prepared on the accrual basis of accounting and include the accounts of the University and all wholly-owned subsidiaries.

The University wholly owns two subsidiaries. Triangle Residential LP is a limited partnership formed in 2005 that owns and operates two apartment buildings, a parking garage and a commercial structure located in the Ford-Euclid-Mayfield Road area. The University is the sole limited partner. The general partner is Triangle Residential LLC, also a wholly-owned subsidiary of the University, formed in 2005. The University, through Triangle Residential LP, plans to operate the properties pending finalization of plans to develop an arts, entertainment and residential complex in the area. All material transactions between the University and its subsidiaries have been eliminated.

Net Asset Categories

Standards for external financial reporting by not-for-profit organizations require that resources be classified for reporting purposes into three net asset categories according to donor-imposed restrictions:

- Unrestricted net assets are available for any purpose consistent with the University's mission. Unrestricted net assets and related activity include the following:
 - All revenues traditionally classified as unrestricted resources of the University, including tuition
 and fees, unrestricted gifts, investment returns on unrestricted funds designated to function as
 endowment, recovery of facility and administrative costs from grants and contracts, and auxiliary
 services revenues.
 - 2) Revenues related to sponsored research and other sponsored program agreements, which are considered exchange transactions.
 - 3) Unrestricted funds functioning similar to endowment and related investment returns.
 - 4) Gifts with donor-imposed restrictions, if the restriction is anticipated to be met within the current fiscal year of the University.
 - 5) Investments in plant assets.
 - 6) All expenses of the University.
- Temporarily restricted net assets include investment returns from endowments and gifts for which
 donor-imposed restrictions have not been met. This restriction on temporarily restricted endowment
 returns (income and realized and unrealized gains and losses) is released when appropriations are
 distributed for use and the funds have been spent. The category also includes pledges receivable and
 life-income gifts for which the ultimate purpose of the proceeds is not permanently restricted.
- Permanently restricted net assets include gifts, trusts and pledges on which donors have imposed the
 restriction that the corpus is maintained in perpetuity and only the investment returns be made
 available for program operations. In the case of trusts, gains and losses are added to the gift amount.
 Gifts restricted by donors to provide loans to students are also included in permanently restricted net
 assets.

Expirations of temporary restrictions on net assets are reported as reclassifications between the applicable classes of net assets. Donor required matching from University funds and donor release or clarification of restrictions is also included in this category.

The Financial Accounting Standards Board ("FASB") issued Accounting Standards Codification ("ASC") 958, "Not for Profit Entities," in August 2008. The standard provides guidance on the net asset classification of donor restricted endowment funds for a not-for-profit organization that is subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act ("UPMIFA") and expands disclosures about an organization's endowment (both donor restricted and board designated funds). The University's Board of Trustees ("Board") has interpreted UPMIFA as requiring the preservation of the original gift as of the gift date of the donor restricted endowment funds absent explicit donor stipulation to the contrary. As a result of this interpretation, the University classifies as permanently restricted net assets, (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor restricted endowment fund that is not classified as permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the University in a manner consistent with the standard of prudence prescribed by UPMIFA.

Contributions

Contributions, including unconditional pledges to give and irrevocable trusts held by others with the University as the beneficiary, are recognized as revenues in the period received or promised. They are classified as unrestricted, temporarily restricted, or permanently restricted net assets depending upon the donor's intent. Conditional pledges become revenue when the conditions are substantially met. Gifts whose restrictions are met in the same fiscal year in which they are received are reported with unrestricted contribution revenues.

Contributions restricted for the acquisition of land, buildings and equipment are reported as temporarily restricted revenues. These contributions are reclassified to unrestricted net assets when the assets are placed in service. Promises to give that are subject to donor-imposed stipulations that the corpus be maintained in perpetuity are recognized as increases in permanently restricted net assets.

Conditional promises to give are not recognized until the conditions on which they depend are substantially met. Contributions of assets other than cash are reported at their estimated fair value at the date of gift. Contributions scheduled to be received after one year are discounted using a market rate (Note 3).

Grants and Contracts (Government and Private)

Revenues from government and private grants and contracts are recognized as earned in accordance with the terms of the grant or contract. Any government payment received before it has been expended is recorded as a refundable advance. Projects funded by government grants that incur expenses prior to payment receipt are recorded as revenue with a corresponding receivable.

Cash and Cash Equivalents

The University considers all highly liquid investments with an original maturity of 90 days or less when purchased as cash and cash equivalents, except those amounts managed by investment managers as part of the investment pool or unspent bond proceeds, which are classified as investments.

Investments

Investments are made within guidelines authorized by the Board. Investments are initially recorded at cost at date of acquisition or fair value at date of donation in the case of gifts. Ownership of marketable securities is recognized as of the trade date. Endowment returns are calculated net of internal and external investment management expenses.

Investments are stated at fair value as defined by ASC 820, "Fair Value Measurements and Disclosures." Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability, i.e., an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The fair value of all debt and equity securities with readily determinable fair value are based on quotations obtained from national securities exchanges. The alternative investments, which are not readily marketable, are carried at estimated fair values as provided by the investment managers. The University reviews and evaluates the values provided by the investment managers and agrees with the valuation methods and assumptions used in determining the fair value of the alternative investments. Those estimated fair values may differ significantly from the values that would have been used had a ready market for these securities existed. Realized gains and losses on investments are included in investment income. Average cost is generally used to determine gains or losses on securities sold. Unrealized changes in the fair market value of investments are shown as net unrealized appreciation or depreciation.

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the University for financial instruments measured at fair value on a recurring basis (Note 6). The three levels of inputs are as follows:

- Level 1 Quoted unadjusted prices in active markets for identical assets or liabilities. An active
 market is one in which transactions occur with sufficient frequency and volume to produce pricing
 information on an ongoing basis. Market price data are generally obtained from exchange or dealer
 markets.
- Level 2 Pricing inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the same term of the assets or liabilities. Inputs are obtained from various sources including market participants, dealers and brokers.
- Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Collections

The University's collections of historically significant artifacts, scientific specimens, and art objects are held for education, research, scientific inquiry, and public exhibition. Their value is not reflected in the University's consolidated financial statements.

Funds Held in Trust by Others

Funds held in trust by others are assets held and administered by outside trustees from which the University derives income or residual interest. Funds held in trust by others are reported at their fair value as of June 30, 2010 and 2009, which approximates the present value of the future income flows from these funds.

Income received from funds held in trust by others is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the University. Income appropriated within the same year is classified as unrestricted. Unrealized changes in the fair market value of investments are shown as net unrealized appreciation or depreciation in permanently restricted net assets.

Asset Retirement Obligations

The University accounts for asset retirement obligations in accordance with ASC 410, "Asset Retirement Environmental Obligations." The University accrues for asset retirement obligations in the period in which they are incurred if sufficient information is available to reasonably estimate the fair value of the obligation.

CASE WESTERN RESERVE UNIVERSITY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2010 IN THOUSANDS OF DOLLARS

Over time, the liability is accreted to its settlement value. Upon settlement of the liability, the University will recognize a gain or loss for any difference between the settlement amount and liability recorded.

Allocation of Certain Expenses

The consolidated statement of activities presents expenses by function. Some expenses — such as depreciation, amortization, and expenses related to the operation of the physical plant — are allocated by square footage. Interest expense is allocated to the functions that derive the greatest benefit from the facilities financed.

Retirement Plans

The University accounts for its defined benefit postretirement plan in accordance with ASC 715 "Compensation - Retirement Plans." The University recognizes the overfunded or underfunded status of a defined benefit postretirement plan as an asset or liability in its consolidated statement of financial position in the year in which the change occurs, with an offsetting impact to unrestricted net assets.

Use of Estimates

Financial statements using accounting principles generally accepted in the United States of America rely on estimates. At June 30, management makes certain estimates and assumptions, which affect assets and liabilities, disclosures of contingent assets and liabilities, and reported revenues and expenses during the period. Actual results may differ from these estimates.

Comparative Information

The consolidated statement of activities includes prior year summarized comparative information in total, but not by net asset category. Such information does not include enough detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the University's consolidated financial statements for the year ending June 30, 2009, from which it was derived.

Income Taxes

The University is exempt from federal income tax to the extent provided under section 501(c)(3) of the Internal Revenue Code. The University is classified as an organization that is not a private foundation under section 509(a) of the Internal Revenue Code because it is described in sections 509(a)(1) and 170(b)(1)(A)(ii) and, as such, gifts to the University qualify for deduction as charitable contributions. The University is exempt from federal income tax, however; it is required to pay federal income tax on unrelated business income. The University did not have any material income tax liabilities for the years ended June 30, 2010 and 2009. ASC 740, "Income Taxes," prescribes a recognition threshold and measurement requirements for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In addition, ASC 740 provides guidance on recognition, classification, accounting in interim periods and disclosure requirements for uncertain tax provisions. The University has no financial reporting requirements associated with ASC 740 for the years ended June 30, 2010 and 2009.

Reclassifications

Certain amounts in the 2009 consolidated financial statements have been reclassified to conform to the 2010 presentation.

2. Accounts and Loans Receivable

Accounts and loans receivable of the University at June 30, 2010 and 2009, were as follows:

	 2010	2009		
Accounts receivable, net:				
Grants, contracts and others	\$ 43,502	\$ 48,675		
Students	2,852	9,948		
Student loans, net	 49,591	 48,659		
	\$ 95,945	\$ 107,282		
Allowances for doubtful accounts:				
Accounts receivable	\$ 3,437	\$ 4,077		
Loans receivable	\$ 1,432	\$ 1,450		

3. Pledges Receivable

Unconditional promises to give are included in the consolidated financial statements as pledges receivable and revenue of the appropriate net asset category. Multi-year pledges are recorded after discounting to the present value of expected future cash flows. Unconditional promises to give at June 30, 2010 and 2009, are expected to be realized in the following periods:

	 2010	 2009		
In one year or less	\$ 8,834	\$ 9,453		
Between one year and five years	35,213	45,338		
More than five years	 17,205	3,725		
	61,252	58,516		
Less: Discount	(5,460)	(3,464)		
Less: Allowance	 (3,130)	(3,704)		
	\$ 52,662	\$ 51,348		

Pledges receivable at June 30, 2010 and 2009 had the following restrictions:

	 2010	 2009
Department programs and activities	\$ 25,111	\$ 22,601
Endowments for scholarships and		
department programs and activities	14,606	19,380
Building construction	 12,945	 9,367
	\$ 52,662	\$ 51,348

Pledges have been discounted at the market rate. Uncollectible pledges totaling \$2,415 (2010) and \$3,534 (2009) were written off against the allowance for uncollectible pledges.

The University had conditional pledge commitments totaling \$27,152 (2010) and \$50,541 (2009).

4. Investments

The University's investments (excluding funds held in trust by others) at June 30, 2010 and 2009, were as follows:

		2	010			20	09	
	Fa	ir Market Value		Cost	Fa	air Market Value		Cost
Cash & cash equivalents	\$	196,572	\$	196,572	\$	77,185	\$	77,176
Certificates of deposit		6,000		6,000		-		-
Domestic stocks		26,132		27,985		17,993		23,088
International securities		29,734		31,313		142,467		154,491
Bonds								
Government and municipal		25,865		25,801		20,391		20,507
Corporate		16,795		16,124		22,262		23,436
Mutual funds		252,192		235,489		201,524		194,230
Derivatives		(21,624)		8,406		55,178		56,723
Limited partnerships and other								
Venture capital		65,841		58,053		57,443		51,758
Private equity		226,315		225,390		210,831		236,017
Hedge funds		321,210		276,342		303,687		287,730
Other		27,647		19,031		47,849		36,860
Equity real estate		90,826		108,885		105,081		109,106
Total	\$	1,263,505	\$	1,235,391	\$	1,261,891	\$	1,271,122

The investments were held for the following purposes:

	2010	2009
Investment pool:		
Endowment	\$ 850,573	\$ 843,952
Donor restricted funds	266,063	268,537
Board designated funds	22,343	21,180
Funds held for the benefit		
of others	 7,649	7,435
Total investment pool	1,146,628	1,141,104
Unpooled investments:		
Endowment	36,015	36,154
Donor restricted funds	779	26
Unexpended bond proceeds	-	8,408
Annuities	49,211	47,409
Unexpended gifts	5,714	5,627
Agency funds	292	264
University investments	 24,866	22,899
Total	\$ 1,263,505	\$ 1,261,891

5. Endowment and Similar Funds

Endowment Funds

The purpose of endowment funds is to generate in perpetuity operating revenue to support specific activities or for general institutional use. Endowments represent only those net assets that are under the control of the University. Gift annuities, interests in funds held in trust by others and pledges designated for the endowment but not yet received are not considered components of the endowment.

Effective June 1, 2009, the state of Ohio adopted legislation that incorporates the provisions outlined in the Uniform Prudent Management of Institutional Funds Act (UPMIFA). UPMIFA stipulates that unless directed otherwise in the gift instrument, donor-restricted assets in an endowment fund are restricted assets until appropriated for expenditure by the institution. Accordingly, the following items are recorded as permanently restricted net assets:

- The original value of initial gifts donated to the permanent endowment.
- The original value of subsequent gifts to the permanent endowment.
- For those endowment funds with donor-specified reinvestment provisions, accumulations to the
 permanent endowment made in accordance with the gift instrument at the time the accumulation is
 added to the fund.

The remaining portion of donor-restricted endowment funds that are not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated and spent in accordance with the endowment purpose by the University.

Similar Funds

The University has made the decision to co-invest and treat in a similar fashion as endowment funds, certain funds that have been purpose-restricted by donors. These funds were not given to the University with the understanding that the gift amount would be maintained in perpetuity; however, the Board has moved to treat these funds in the same fashion as an endowment fund. Accordingly, the Board, at its option, may elect to change that treatment and spend these funds in accordance with donor wishes without the constraints of the University endowment spending formula. These funds follow the same rules as above; however, no portion is permanently restricted.

			Te	mporarily	Per	manently	Total			
	Unı	restricted	Re	estricted	Re	estricted	2010		2009	
Donor restricted endowment										
funds	\$	(13,601)	\$	411,626	\$	489,256	\$ 887,281	\$	883,063	
Donor temporarily restricted										
funds		-		266,874		-	266,874		267,059	
Total endowment and similar									_	
funds	\$	(13,601)	\$	678,500	\$	489,256	\$ 1,154,155	\$	1,150,122	

Investment Pool

The Board's interpretation of its fiduciary responsibilities for endowment and similar funds is to preserve intergenerational equity to the extent possible. This principle holds that future beneficiaries should receive at least the same level of economic support that the current generation enjoys. To that end, investment goals are formulated to earn returns over the long-term that equal or exceed the board-approved distribution rates plus the impacts of inflation. The University's endowment and similar funds are invested in a broadly diversified portfolio designed to produce long-term rates of return that sustain or increase the real spending contribution from endowed and similar assets and to mitigate downturns in a single sector.

Unless otherwise directed in the gift instrument, both endowment and similar funds are pooled for efficient investment purposes.

	2010	%	2009	%
Investment pool:				
Cash & cash equivalents	\$ 204,840	17.7%	\$ 123,119	10.7%
Investments	911,796	79.0%	989,370	86.0%
Unpooled investments	36,794	3.2%	36,180	3.2%
Cash awaiting investment	725	0.1%	1,453	0.1%
Total Assets	\$ 1,154,155	100.0%	\$ 1,150,122	100.0%

A unit market value for the pool is used to account for pooled transactions. The unit market values are \$36.42 (2010) and \$35.82 (2009). The total investment return for the pooled investments, net of external manager fees, approximated 7.19% (2010) and -19.01% (2009).

Spending Policy

The Board has approved an endowment spending policy for pooled investments based on a hybrid formula. The objective of this two-pronged approach is to provide support for operations, preserve intergenerational equity, and insulate programming supported by endowment and similar funds from short-term fluctuations in the investment markets. The two components are:

- A constant growth component seeks to provide growth in annual spending equal to the rate of academic inflation as measured by the Higher Education Price Index.
- A market value component based on 5% of the average of the three previous calendar year-end market values.

Specific appropriation for expenditure of funds under the policy occurs each spring when the Board approves the operating budget for the following year. The fiscal 2010 pooled endowment and similar funds spending allocation was \$2.16 per unit totaling \$69,536. For fiscal 2009, pooled endowment and similar funds spending allocation was \$2.19 per unit totaling \$69,354.

While the policy provides guidance for the level of spending permitted (allocation), the actual spending will vary from the spending allocation based on the timing of actual expenditures. Funds are transferred from the investment pool to the University's operating account after they have been spent in accordance with the endowment and similar funds requirements. The physical movement of cash and investments between the investment pool and operating accounts occurs on a periodic basis as determined by the University and its process to maintain the proper balance between liquidity and remaining invested.

For years where actual investment return exceeds actual approved spending, the difference remains in temporarily restricted net assets; years in which the actual endowment and similar funds return is less than distributions under the policy, the shortfall is covered by realized returns from prior years. The fiscal 2010 pooled endowment and similar funds distribution was funded from a combination of current year investment income and prior year accumulated realized gains. For fiscal 2009, pooled endowment and similar funds distribution was funded from accumulated realized gains.

In addition to the general distribution described above, the Board has authorized a temporary supplemental distribution of previously reinvested income and realized appreciation to support certain development-related activities. This distribution, which is slated to phase out by 2015, totaled \$7,869 (2010) and \$7,912 (2009).

CASE WESTERN RESERVE UNIVERSITY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED JUNE 30, 2010 IN THOUSANDS OF DOLLARS

Changes in endowment and similar funds net assets for fiscal year 2010 are as follows:

		Temporarily		Per	rmanently	tly To			tal		
	Unr	Unrestricted		estricted	R	estricted		2010		2009	
Endowment and similar funds net											
assets, beginning of year	\$	(22,709)	\$	694,724	\$	478,107	\$	1,150,122	\$	1,477,483	
Investment return:											
Investment income		-		10,301		-		10,301		15,576	
Realized and unrealized gains											
(losses)		-		64,052		-		64,052		(292,025)	
Total investment return		-		74,353		-		74,353		(276,449)	
Contributions		-				11,149		11,149		27,066	
Current year withdrawals		-		(6,525)		-		(6,525)		-	
Current year expenditures		-		(74,944)		-		(74,944)		(77,978)	
Recovery of prior year deficits of											
underwater endowments		9,108		(9,108)		-		-			
Endowment and similar funds net											
assets, end of year	\$	(13,601)	\$	678,500	\$	489,256	\$	1,154,155	\$	1,150,122	

Occasionally, the fair market value of assets associated with individual donor-restricted endowment funds may fall below the value of the original gift amounts. When deficits exist in donor-restricted funds, they are classified as a reduction of unrestricted net assets. Deficits of this nature reported in unrestricted net assets were \$13,601 (2010) and \$22,709 (2009). These deficits resulted from unfavorable market fluctuations that occurred after the investment of recently established endowments, and authorized appropriation that was deemed prudent.

Of the amount classified as temporarily restricted endowment net assets, \$411,626 (2010) and \$435,371 (2009) represents the portion of perpetual endowment funds subject to time and purpose restrictions under Ohio's enacted version of UPMIFA.

6. Fair Value Measurements

Financial instruments carried at fair market value as of June 30, 2010 by the ASC 820 valuation hierarchy are as follows:

	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant nobservable Inputs (Level 3)	Total
Investments		,	,		•	
Cash & cash equivalents	\$	45,633	\$ 148,030	\$	2,909 \$	196,572
Certificates of deposit		6,000	-		=	6,000
Domestic stocks		24,747	1,385		-	26,132
International securities		12,636	17,098		=	29,734
Bonds						
Government and municipal		10,130	15,735		-	25,865
Corporate		6,648	10,147		-	16,795
Mutual funds		237,032	-		15,160	252,192
Derivatives		268	(21,726)		(166)	(21,624)
Limited partnerships and other						
Venture capital		-	-		65,841	65,841
Private equity		-	-		226,315	226,315
Hedge funds		-	65,655		255,555	321,210
Other		146	74		27,427	27,647
Equity real estate		213	-		90,613	90,826
Total investments		343,453	236,398		683,654	1,263,505
Funds held in trust by others		-	<u> </u>		255,729	255,729
Pension Plan Assets (Note 9)		1 616				1 616
Cash & cash equivalents		1,616	-		-	1,616
Mutual funds		34,747	-		-	34,747
Limited partnerships and other					47 100	47.100
Hedge funds		-	-		47,123	47,123
Other		-	-		590	590
Equity real estate		26.262	-		2,289	2,289
Total pension plan assets (note 9)		36,363	-		50,002	86,365
Total assets at fair market value	\$	379,816	\$ 236,398	\$	989,385 \$	1,605,599
Interest rate swaps payable	\$	-	\$ 24,838	\$	- \$	24,838

Level 3 Investment Information

Investments included in Level 3 consist primarily of the University's ownership in alternative investments (principally limited partnership interests in hedge funds, private equity, real estate, real assets and other similar funds), beneficial interests in funds held in trust by others, and portions of investments in the pension assets. Level 3 investments are more difficult to value due to the following:

- The value of certain alternative investments represents the ownership interest in the net asset value of the respective partnership.
- The fair values of the securities held by limited partnerships that do not have readily determinable fair values are determined by the general partner based on appraisals or other estimates that require varying degrees of judgment.
- If no public market exists for the investment securities, the fair value is determined by the general partner taking into consideration, among other things, the cost of the securities, prices of recent significant placements of securities of the same issuer, subsequent developments concerning the companies to which the securities relate, or other estimates requiring varying degrees of judgment. The University regularly reviews, evaluates and performs significant due diligence around these investments to ensure that the values provided by the investment managers are appropriate measures of fair value. The University agrees with the valuations and assumptions used in determining the fair value of these investments.

A roll forward of the consolidated statement of financial position amounts for financial instruments classified by the University within Level 3 of the fair value hierarchy is as follows:

													(Other &		
	M	I utual	C	ash &		Int'l	V	Venture	Private	Hedge	Eq	uity Real	Fu	ınds Held		
	F	unds	De	rivatives	Se	ecurities	(Capital	Equity	Funds		Estate	b	y Others		Total
Beginning balance, July 1, 2009	\$	13,378	\$	-	\$	56,438	\$	57,443	\$ 210,831	\$ 343,402	\$	107,416	\$	256,601	\$ 1	,045,509
Realized gains (losses) and investment income		8		(2,093)		11,344		(691)	2,690	1,408		(3,133)		(5,315)		4,218
Unrealized gains (losses)		1,734		(165)		3,626		960	26,111	37,737		(14,292)		27,749		83,460
Net purchases, issuances and settlements		40		5,001		(71,408)		8,129	(13,317)	(14,215)		2,911		4,711		(78,148)
Transfers out of Level 3		-		-		-		-	-	(65,654)		-		-		(65,654)
Ending balance, June 30, 2010	\$	15,160	\$	2,743	\$	-	\$	65,841	\$ 226,315	\$ 302,678	\$	92,902	\$	283,746	\$	989,385

The net realized and unrealized gains and losses in the table above are included in the University's consolidated statement of activities in one of two financial statement lines; *Investment returns*, *reduced by operating distribution above* or in the *Net appreciation (depreciation) in the fair market value of investments*. In the case of pension assets, net realized and unrealized gains and losses are recognized in the financial statement line *Pension plan changes other than periodic benefit costs*.

The pricing inputs and methods described above could produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the University believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

In 2009, new guidance related to the Fair Value Measurement standard was issued for estimating the fair value of investments in investment companies (limited partnerships) that have a calculated value of their capital account or net asset value ("NAV") in accordance with, or in a manner consistent with U.S. generally accepted accounting principles ("US GAAP"). As a practical matter, the University is permitted under US GAAP to estimate the fair value of an investment at the measurement date using the reported NAV without further adjustment unless the entity expects to sell the investment at a value other than NAV or if the NAV is not

calculated in accordance with US GAAP. The University's investments in private equity, real estate and certain hedge funds in the absolute return portfolio are fair valued based on the most current NAV.

The University performs additional procedures including due diligence reviews on its investments in investment companies and other procedures with respect to the capital account or NAV provided to ensure conformity with US GAAP. The University has assessed factors including, but not limited to, managers' compliance with Fair Value Measurement standard, price transparency and valuation procedures in place, the ability to redeem at NAV at the measurement date, and existence of certain redemption restrictions at the measurement date.

The guidance also requires additional disclosures to enable users of the financial statements to understand the nature and risk of the University's investments. Furthermore, investments which can be redeemed at NAV by the University on the measurement date or in the near term are classified as Level 2. Investments which cannot be redeemed on the measurement date or in the near term are classified as Level 3. The new guidance did not materially affect the University's consolidated financial statements.

	Fa	Fair Market Unfunded		Redemption		
Category		Value	Value Commitments		Frequency	Notice Period
Limited partnerships and other						
Venture capital (a)	\$	65,841	\$	37,573	n/a	
Private equity (b)		226,315		108,621	n/a	
Hedge funds (c)		255,555		5,694	varies	30 - 60 days
Other (d)		27,427		25,269	n/a	
Equity real estate (e)		90,613		19,448	n/a	
	\$	665,751	\$	196,605		

- (a) This category includes several private equity funds that invest primarily in technology, health care or clean technology industries. While the portfolio is U.S. centric, there are small allocations to companies in foreign markets. The funds typically provide money and resources to entrepreneurs to finance a start-up company or product, with the hope that the company experiences exceptional growth and therefore would produce a successful investment. The funds invest at different stages of a company's growth, some very early and others at a later stage where the company may already produce revenues. The valuations for these investments have been estimated using the manager's fair market values, which have been vetted to make sure they meet the ASC 820 guidelines. These investments can never be redeemed with the funds. As these investments age in duration, distributions will be received from these funds as the underlying portfolio companies are sold in the market. It is estimated that the underlying investments within the funds would be fully liquidated over the next 7-12 years.
- (b) This category includes several private equity funds that invest across all industries. While the portfolio is U.S. centric, there has been an increasingly larger allocation to companies in foreign markets. The funds typically invest capital into more mature companies for a minority or majority of ownership and through operational and financial expertise, generate a return of capital greater than the original amount invested. The valuations for these investments have been estimated using the manager's fair market values, which have been vetted to make sure they meet the ASC 820 guidelines. These investments can never be redeemed with the funds. As these investments age in duration, distributions will be received from these funds as the underlying portfolio companies are sold in the market. It is estimated that the underlying investments within the funds would be fully liquidated over the next 7-12 years.
- (c) This category includes hedge fund investments across a multitude of strategies including long/short equity, long/short commodity, global macro, multi-strategy, event-driven, credit, fund of hedge funds, and emerging markets. The vast majority of these investments are U.S. based, but some may invest

internationally. Investment managers may make investment decisions based on top down macroeconomic analysis or bottom up company or theme specific analysis; managers may shift portfolios from net long to net short positioning but on balance tend to carry a net long exposure within their portfolios. The estimated fair values of the investments are received on a monthly basis from the fund administrators. Final valuations are typically received around mid-month for most funds but in some instances funds will report final valuations on a quarterly basis in accordance with the reporting period specified in the fund legal documents. Fund liquidity varies across the hedge fund category from monthly, quarterly, annually, and up to a maximum period of three years.

- (d) This category includes various direct private investments as well as private funds that do not fall within the other categories listed. Examples would include an Eastern Europe agriculture fund, some private U.S. oil and gas partnerships and various stakes in local private organizations. For the funds, the valuations have been estimated using manager's fair market values, which have been vetted to make sure they meet the ASC 820 guidelines. These investments can never be redeemed with the funds. As these investments age in duration, distributions will be received from these funds as the underlying portfolio companies are sold in the market. It is estimated that the underlying investments within the funds would be fully liquidated over the next 7-10 years.
- (e) This category includes private real estate funds that invest primarily in the United States. Some of these private partnerships also make investments internationally, primarily in Europe, India and Brazil. The private funds make investments in various real estate types, such as office, industrial, retail and multifamily properties. The valuations for these investments have been estimated using the manager's fair market values, which have been vetted to make sure they meet the ASC 820 guidelines. These investments can never be redeemed with the funds. As these investments age in duration, distributions will be received from these funds as the underlying properties are sold in the market. It is estimated that the underlying investments within the funds would be fully liquidated over the next 5-7 years.

Derivative Information

The use of financial derivative instruments is governed by the University's Investment Policy Statement, which is approved and overseen by the Investment Committee of the Board of Trustees. The University assumes many risks as a result of its investment decisions and investment holdings. Many risks are discussed in the Investment Policy Statement:

- Manager risk the risk that a manager underperforms similar managers, benchmarks, or appropriate indices.
- **Benchmark risk** the risk of harm caused by constructing, selecting, or managing to an inappropriate benchmark.
- **Peer risk** the risk that one's peers generate better investment performance, thereby boosting the relative size of their endowments and enhancing their competitive advantage.
- Market risk the risk that the value of an investment will decrease due to market moves.
- **Interest rate risk** the risk that an investment's value will change due to a change in the absolute level of interest rates, the spread between two rates, the shape of the yield curve, or any other interest rate relationship.
- **Concentration** the risk of being too concentrated in one particular security, manager, strategy, sector or asset class, thus being vulnerable to poor performance stemming from lack of diversification.
- **Absolute return risk** the ability to generate positive absolute returns, not just in favorable markets, but also in uncertain and negative phases measured over a business cycle.
- **Currency risk** the risk that currency fluctuations or trends reduce the value of investments in non-U.S. markets.
- **Commodity risk** refers to the uncertainties of future market values and the size of future income caused by fluctuation in the prices of commodities (energy, agricultural, precious and industrial metals) due to demand/supply imbalances.

- **Leverage** the risk that significant volatility or losses will be generated by the use of debt designed to magnify returns.
- Counterparty risk the risk that one party to a transaction does not make complete or timely payment of margin, swap cash flow, bond proceeds, or other similar payments.
- **Credit risk** the possibility that a bond issuer will default by failing to pay interest or repay principal in a timely manner.
- **Tail risk** a form of portfolio risk that arises when the possibility that an investment will move more than three standard deviations from the mean is greater than what is shown by a normal distribution.
- **Liquidity risk** the inability to sell or trade securities at fair market value within a short period of time; also, the risk that sufficient cash is not maintained, or cannot be accessed, to meet short-term obligations.
- **Inflation risk** the risk that rising prices significantly erode the effective purchasing power of the portfolio, as measured by the University's cost inflation.
- Shortfall risk the risk that investment returns will be lower than expected, causing a failure to accomplish investment or financial objectives.

The University seeks to mitigate these risks by using derivative transactions. At the macro level of the investment portfolio, derivative transactions also create cost-effective beta exposure that may replace a fund or investment manager, add alpha, support liquidity management, and reduce the impact of extreme negative market conditions. The derivative instruments used include futures, total return swaps, and over-the-counter options.

- Futures: An Equity Index Future is a standardized obligation to buy or sell a market index, at a certain date in the future (settlement date), at a specified price (futures price). Equity Index Futures are typically cash-settled. Trading Medium: Exchange A single clearing house (e.g., Options Clearing Corporation, for the Chicago Board Options Exchange) is the counterparty to both parties involved in the contract. Futures trade a premium or discount to the cash index level based on the following theoretical formula: Futures Fair Value = Cash Index Value + Expected Interest Income prior to contract expiry Expected Dividend Income prior to contract expiry Expected Lending Income prior to contract expiration. The value of a futures contract converges to that of the underlying index at expiration. The investor posts an initial margin and a maintenance margin which represents a small portion of the overall notional value (usually 12%-18% of the notional value). Collateral between the counterparties is exchanged daily based on the mark to market performance of the futures contract. Used to gain beta exposure to an index on the long side and to hedge out beta exposure on the short side. Used primarily as a manager replacement strategy.
- Total Return Swap (TRS): A TRS is a non-standardized agreement whereby one party makes periodic cash payments based on a set rate (e.g., LIBOR) while another party makes periodic cash payments based on the total return of an underlying index. The total return payer agrees to pay the total return of the underlying index to the total return receiver. The total return receiver agrees to receive future total return, and pay periodic payments to the total return payer. Trading Medium: Over-The-Counter (OTC). Total Return Swaps offer synthetic exposure to beta returns while avoiding the transaction and administrative costs of owning the actual underlying equity shares. Subject to counterparty credit risk; if collateral is posted between parties, counterparty credit risk can be mitigated. Transacted via ISDA/CSA agreement between counterparties. There is no initial or maintenance margin posting. Collateral between the counterparties is exchanged daily based on the mark to market performance of the swap. Used to gain beta exposure to an index on the long side and to hedge out beta exposure on the short side. The swap resets on a periodic basis (monthly or quarterly), at which point the LIBOR rate is reset and the gains/losses cash settled. A new notional value reflecting the settled gains/losses is established at this point. The next measurement begins with the new notional value. There may be a breakup fee if the swap is terminated earlier than its expiration date. Used primarily as a manager replacement strategy.

• Options: Options or Option structures are a non-standardized agreements whereby one party makes periodic cash payments based on a set rate (e.g., LIBOR) while another party makes periodic cash payments based upon a predefined, linear or non-linear payoff profile based on an individual option or a combination of individual options. Trading Medium: over-the-counter (OTC). Transacted via ISDA/CSA agreement between counterparties. Subject to counterparty credit risk; if collateral is posted between parties, counterparty credit risk can be mitigated. Options/Option structures allow investors to customize the risk/return profile of existing portfolios. For example: Investors who are underweight equities and have a moderately positive outlook can obtain enhanced equity exposure by capping returns with or without a leveraged payoff. More bearish investors can opt for downside protection to reduce risk. Collateral between the counterparties is exchanged daily based on the mark to market performance of the Option or Option Structure. At maturity the Option or Option structure is cash settled. Prior to maturity, Option/Option structures may trade above or below their intrinsic value due to various factors such as time, volatility, interest rates, skew, delta, gamma etc. The value eventually converges to intrinsic value at maturity. Used for beta replacement strategies, alpha strategies or hedging strategies.

The following table provides detailed information on the derivatives included in the investment portfolio as of June 30 and where they are located in the consolidated statements of financial position.

							2010		
			Notional		el 1 Fair	Le	vel 2 Fair	Level 3 Fair	
Location	Derivative Type	ative Type Amount			Value		Value	Value	
Investment	ts								
	Total return swaps	\$	109,972	\$	-	\$	(7,766)	\$	(166)
	Interest rate swaps		74,811		-		(73)		-
	Options (over-the-counter)		222,598		268		(13,887)		
				\$	268	\$	(21,726)	\$	(166)
							2009		
		N	Votional	Lev	el 1 Fair	Le	vel 2 Fair	Le	vel 3 Fair
Location	Derivative Type	A	Amount		Value		Value		Value
Investment	ts								
	Options (over-the-counter)	\$	66,309	\$	46	\$	34,437	\$	-
	Futures contracts		51,828		20,695		_		_
				\$	20,741	\$	34,437	\$	_

The following table provides detailed information on the effect the derivatives had on the overall performance of the investment portfolio which is reflected in the consolidated statement of activities:

Location	Derivative Type		2010		2009
Investment	Income				
	Options (over the counter)	\$	38,328	\$	21,422
	Futures contracts		(8,188)		(70,726)
		\$	30,140	\$	(49,304)
Unrealized g	gains (losses)	Ф	(10.052)	Ф	
	Total return swaps	\$	(10,962)	\$	11 200
	Options (over the counter)		(19,068)		11,309
	Futures contracts				(58)
		\$	(30,030)	\$	11,251

7. Property, Plant, Equipment and Books

Property, plant, equipment and books are stated at cost, less accumulated depreciation. Depreciation is computed on the straight-line method over the estimated useful life of 28 years for buildings, 5 to 12 years for equipment, and 10 years for books.

Components of property, plant, equipment and books are as follows:

	2010		2009	
Land and land improvements	\$	39,009	\$	39,009
Building and building improvements		1,087,176		1,064,490
Equipment and software		261,826		248,975
Library books		34,303		32,855
Construction-in-progress		37,007		38,777
		1,459,321		1,424,106
Less: accumulated depreciation		(689,875)		(629,018)
	\$	769,446	\$	795,088

The above assets include \$492,376 leased from the Ohio Higher Education Facility Commission (OHEFC). The University may purchase each of the leased assets for a nominal amount at the end of the lease period. Therefore, these assets have been capitalized and are included in the above listing. Also included in the University's consolidated financial statements is the obligation for related bonds issued by the OHEFC.

8. Notes and Bonds Payable

Notes and bonds payable are as follows:

_	Interest Rate	Maturity	2010	2009
Ohio Higher Education Faci		revenue notes a		
Series 1988	7.85 - 7.90%	2010-2013	\$ 22,899	\$ 23,801
Series 1990	6.50 - 7.13%	2010-2020	11,650	11,650
Series 1994	6.00 - 6.25%	2014-2018	20,000	20,000
Series 1997	4.90 - 6.25%	2010-2014	7,785	8,920
Series 2001	Variable	2010-2022	12,975	13,285
Series 2002A	Variable	2023-2031	64,875	64,875
Series 2004A	3.625 - 5.00%	2016-2034	75,670	75,670
Series 2006	3.75 - 5.25%	2012-2044	82,490	82,490
Series 2008A	Variable	2030-2044	60,000	60,000
Series 2008B	Variable	2030-2044	67,500	67,500
Series 2008C	4.00 - 5.00%	2014-2033	50,490	50,490
U.S. Government housing be	onds:			
Series 1966	3.00 - 3.50%	2010-2016	690	845
Series 1971	3.00%	2010-2016	785	905
	r. a · ·			
Ohio Higher Education Faci	•			62,000
	.2543%	not to exceed	63,000	63,000
Ohio Higher Education Faci	lity Commission	capital lease:		
C	6.75%	2010-2018	614	681
	4.12%	2010-2018	6,548	12,293
Charter One Bank	3.25%		_	100
Charter One Bank	3.23/0			100
Compass Group USA, Inc.	-n/a-	2010-2019	3,300	3,750
IIIID I oom				
HUD Loan: Part A	4.96%	2010-2041	12,448	12,617
Part B	5.33%	2010-2041	4,280	4,335
rait B	3.3370	2010-2041	567,999	577,207
Unamortized Bond Premium			301,777	377,207
Ohio Higher Education Fac		n·		
Series 2004A	cinty Commissio	11.	2,017	2,174
Series 2004A Series 2006			7,314	7,704
Series 2008C			1,968	2,131
Series 2000C			11,299	12,009
			11,499	12,009
			\$ 579,298	\$ 589,216

The fair market value of the University's notes and bonds payable is approximately \$589,298 (2010) and \$587,886 (2009). These values were estimated utilizing the discounted future cash outflows at rates for similar debt.

The U.S government housing bonds are collateralized by securities and pledges of net revenues from the University's student housing and dining facilities.

The Ohio Higher Education Facility Commission (OHEFC) authorized a \$63,000 tax-exempt commercial paper program in February 2000 to provide construction funds for several approved capital projects and to refinance earlier projects. In November 2008, the OHEFC authorized a \$27,000 expansion of that program, to a total size of \$90,000, to provide funding for future projects. The University has issued no additional commercial paper pursuant to the \$27,000 of new authority, and the amount outstanding under this program as of June 30 is \$63,000, with maturities not exceeding 270 days from the issuance date. All commercial paper issued under the terms of the program must mature no later than February 1, 2030. The average annual interest rate for this program was .38% (2010) and 1.14% (2009).

The University has total revolving lines of credit in the amount of \$60,000 with two financial institutions of \$30,000 each to finance working capital. Both lines are subject to review and renewal annually. There were no amounts outstanding at June 30, 2010.

In May 2008, the OHEFC series 2008 bonds were issued to refinance the OHEFC series 2004B bonds. The amount refinanced was \$177,826. The variable portion of the debt is supported by two lines of credit with financial institutions. The unamortized balance of deferred financing fees is included in prepaid expenses and other assets. The balance was \$1,355 (2010) and \$1,367 (2009).

Principal payment requirements for bonds, notes, and capital lease obligations for the next five years and thereafter are as follows:

	Sc	heduled		Tota	l Maximum			
	Principal		Ου	itstanding	P	Principal		
_	Pa	Payments		VRDO's	Pa	Payments		
2011	\$	9,709	\$	121,070	\$	130,779		
2012		9,505		58,070		67,575		
2013		10,534		58,070		68,604		
2014		10,388		15,570		25,958		
2015		11,811		15,570		27,381		
Thereafter		516,052		(268,350)		247,702		
_	\$	567,999	\$		\$	567,999		

The University has letter of credit agreements, standby bond purchase agreements and a liquidity agreement with various financial institutions to purchase the University's variable rate demand obligations ("VRDO's") and commercial paper if they cannot be remarketed. Outstanding VRDO's in the above table represent amounts payable in the event that bonds are tendered but not successfully remarketed.

Interest payments for fiscal year 2010, including payments for variable rate debt, were \$16,732. Interest payments under interest rate swap agreements during fiscal 2010 totaled \$6,041. See Note 12.

Certain borrowing agreements require that the University comply with certain covenants. The University is in compliance with these provisions as of June 30, 2010.

9. Retirement Plans

The University has both defined benefit and defined contribution pension plans for its employees. In accordance with provisions of the Employee Retirement Income Security Act of 1974 ("ERISA"), the University has established a trust to hold plan assets for its defined benefit plan. The funded status of the University's defined benefit plan is as follows:

	 2010	 2009
Benefit obligation at June 30	\$ 118,267	\$ 103,584
Fair value of plan assets at June 30	 86,365	 78,022
Funded status at June 30	\$ (31,902)	\$ (25,562)
Accumulated benefit obligation	\$ 117,137	\$ 102,999

Benefit plan costs for the defined benefit plan are as follows:

	2	2010		2009
Net periodic benefit cost	\$	4,023	\$	1,900
Employer contributions		442		-
Benefits paid		3,128		2,769

Estimated benefits expected to be paid under the defined benefit plan for the next five years are as follows:

Fiscal 2011	\$ 3,428
Fiscal 2012	\$ 4,417
Fiscal 2013	\$ 4,518
Fiscal 2014	\$ 5,626
Fiscal 2015	\$ 4,564

Amounts expected to be paid between 2016 and 2020 total \$36,222. The University's estimated employer contribution for the defined benefit plan in fiscal 2011 will depend on the results of the July 1, 2010 actuarial valuation.

Weighted-average assumptions used to determine the benefit obligation and benefit plan costs are as follows:

	2010	2009
Benefit obligation:		
Discount rate	6.25%	6.50%
Rate of compensation increase	4.25%	4.50%
Measurement date	6/30/10	6/30/09
Census date	7/1/09	7/1/08
Net periodic benefit cost:		
Discount rate	6.50%	7.00%
Expected return on plan assets	8.50%	8.50%
Rate of compensation increase	4.50%	4.50%

The expected long-term rate of return for the defined benefit plan was estimated using market benchmarks for equities and bonds applied to the plan's target asset allocation. The expected return on equities was computed utilizing a valuation framework that projected future returns based on current equity valuations rather than

historical returns. Management estimated the rate by which the plan assets would outperform the market in the future based on historical experience adjusted for changes in asset allocation and expectations for overall lower future returns on equities compared to past periods.

The investment objective for the defined benefit plan is to maximize total return with tolerance for slightly above average risk, in order to meet the obligations that the University has to its plan beneficiaries. To accomplish this objective, the University has established a broadly-diversified asset allocation strategy that includes absolute return strategies (50%), equity investments (30%), real estate (10%), and inflation-indexed bonds and cash (10%). The weightings of the investments relative to each other in the total portfolio fluctuate as market conditions vary; they are adjusted regularly to remain within acceptable ranges.

The weighted-average asset allocation for the defined benefit plan is as follows:

	2010	2009
Equity securities	62.00%	66.00%
Fixed income securities	33.00%	29.00%
Real estate	3.00%	3.00%
Other	2.00%	2.00%
Total	100.00%	100.00%

The amounts recognized in the University's consolidated statements of financial position and in unrestricted net assets related to the defined benefit plan are as follows:

	 2010	2009
Statement of financial position: Net balance sheet liability	\$ (31,902)	\$ (25,562)
Unrestricted net assets: Prior service costs Actuarial losses	\$ 684 37,766	\$ 1,020 34,671
Amount recognized as a reduction of unrestricted net assets	\$ 38,450	\$ 35,691

The estimated amortization of prior year service costs expected in fiscal 2011 totals \$336.

Components of the net periodic benefit cost and other changes in plan assets that are recognized in the consolidated statement of activities for fiscal year 2010 are as follows:

Change in actuarial losses	\$ 3,095
Amortization of prior service cost	 (336)
Total loss recognized in unrestricted net assets	2,759
Net periodic benefit cost	4,023
Employer contributions	 (442)
Total loss recognized in the statement of activities	\$ 6,340

Benefit plan costs for the defined contribution plan are \$18,494 (2010) and \$17,652 (2009).

10. Commitments and Contingencies

In its normal operations, the University is subject to various claims and lawsuits. In management's opinion, the resolution of these contingencies will not have a significant adverse effect on the University's financial position, operations, or cash flows.

In April 2006, the Boards of University Hospitals Health System and the University approved a new affiliation agreement between the School of Medicine and University Hospitals of Cleveland ("UHC"). This agreement significantly strengthened the historical relationship between the entities through the creation of the Case Medical Center, a virtual entity that encompasses certain teaching, research and clinical activities of the School of Medicine and UHC.

In May 2002, the University entered into an agreement with the Cleveland Clinic Foundation ("CCF") to form a new medical education and research program, the Cleveland Clinic Lerner College of Medicine ("CCLCM"). Beginning in 2004, research grants from the National Institutes of Health to support work by CCF-based investigators were awarded to and administered through the University by CCLCM, which operates as an academic unit of the School of Medicine. Expenditures for research conducted under this joint agreement totaled \$88,530 (2010) and \$89,962 (2009).

The University is self-insured for workers compensation and employee and student medical coverage. Property is commercially insured with an aggregate deductible of \$700. The University also carries general liability insurance with a deductible of \$100 per occurrence. The University believes its reserves for self-insured risks and the deductible portion of insured risks are sufficient.

The expected cost to complete construction in progress is approximately \$10,669.

11. Related Party Transaction (Utilities)

In 1998, the University entered into a thirty-year agreement with the Medical Center Company (a cooperative utility company formed by and serving institutions in the University Circle area) to purchase chilled water and other utilities for several University buildings. The amounts purchased were \$23,412 (2010) and \$22,692 (2009). No obligation associated with this agreement is recorded in the accompanying consolidated financial statements.

12. Derivatives and Other Financial Instruments

The University uses floating-to-fixed interest rate swap agreements of various durations to manage both its funding cost and the interest rate risk associated with variable rate debt. Under these swap agreements, the University pays a fixed rate and receives from its counterparty a variable rate payment, each calculated by reference to specified notional principal amounts during the agreement period. Operations are charged the variable rate interest on the corresponding bonds; the difference between the fixed and variable interest amounts under the swap agreements is recorded in non-operating revenues and expenses as investment and other income.

The University follows accounting guidance that defines fair value, establishes a framework for measuring fair value and expands disclosure requirements about fair value measurements, including derivatives. The University's interest rate swaps are valued by an external swap consultant that uses the mid-market levels, as of the close of business, to value the agreements. The valuations provided are derived from proprietary models based upon well-recognized financial principles and reasonable estimates about relevant future market conditions and the University's credit worthiness. The University's interest rate swap arrangements have inputs that can generally be corroborated by market data and are classified as Level 2 in the fair value hierarchy.

At June 30, 2010 the University has six interest rate swap agreements to exchange variable-rate debt for fixed-rate obligations without the exchange of the underlying principal amount. Net payments or receipts under the swap agreements are recorded as adjustments to investment and other income and the incremental expense is disclosed in the table below. Under two agreements in effect at June 30, 2010, the counterparty pays the University a variable interest rate equal to the Securities Industry and Financial Markets Association (SIFMA) index, and under four other agreements, the counterparty pays a variable interest rate equal to a percentage of the one month London Interbank Offered Rates (LIBOR). The following table provides detailed information on the interest rate swaps at June 30, 2010, with comparative fair values for June 30, 2009. The number of swaps is reported based on notional amount. Information related to the interest rate swap agreements to which the University is a party, including the associated OHEFC borrowing, where applicable, and the liability recognized in the consolidated statements of financial position are as follows:

lotional Amount	Interest	Commencement	Termination	Basis	Le	2010 vel 2 Fair N	/Iarke	2009 et Value
\$ 12,975 15,000	4.34% 4.43%	Jun. 5, 2002 Sept. 25, 2002	Jun. 5, 2022 Sept. 25, 2022	LIBOR LIBOR	\$	(2,331) (3,509)	\$	(1,858) (2,752)
15,000	3.60%	Aug. 4, 2004	Aug. 1, 2034	LIBOR		(2,237)		(1,452)
35,000	3.81%	Aug. 12, 2004	Oct.1, 2022	LIBOR		(7,717)		(5,588)
100,000	3.37%	Jan. 2, 2007	Jan. 1, 2012	SIFMA		(4,336)		(4,922)
100,000	3.37%	Jan. 1, 2012	Jan. 1, 2017	SIFMA		(4,708)		(2,464)
					\$	(24,838)	\$	(19,036)

Changes in the fair value of derivative instruments are recorded in non-operating revenues and expenses as investment and other income. The provisions of the swap agreements require that on a weekly basis the University place into an escrow fund collateral sufficient to limit the counter-party's financial exposure to the University to no more than \$20,000. The University had placed \$4,767 (2010) and \$0 (2009) into such a fund, which is shown in *Cash and cash equivalents* on the consolidated statements of financial position.

Interest expense recorded for the swap agreements in the non-operating activities for the year ended June 30 was \$6,041 (2010) and \$4,091 (2009).

13. Commonfund Short Term Investment Fund

As part of its investment portfolio, the University had an investment in the Commonfund Short Term Investment Fund (CSTIF) of \$19,550. On September 27, 2008, the Commonfund Short Term Investment Fund (CSTIF) trustee terminated the fund and began an orderly liquidation of its assets. The University received distributions of its entire investment from the trustee in the amounts of \$2,156 (2010) and \$17,394 (2009).

14. Subsequent Events

The University has performed an evaluation of subsequent events through October 13, 2010, the date on which the consolidated financial statements were issued.

	Catalog of Federal Domestic Assistance	Pass Through Entity Identifying		
FEDERAL GRANTOR/PROGRAM TITLE	Number	Number	Expe	enditures
Research and Development and Research Training Cluster - University				
Research and Development - University				
Department of Agriculture				
Direct Programs Other Department of Agriculture Programs	10.000		\$	2,021
Pass Through Programs	10.000		ψ	2,021
University of Maryland	10.206	USM-GR-02557-A10		24,862
				,
Department of Agricult	ture Subtotal			26,883
Department of Commerce Direct Programs				
Measurement and Engineering Research and Standards	11.609			87,438
Pass Through Programs	11.007			07,430
Ohio State University Research Foundation	11.417	RF01125890		4,727
Ohio State University Research Foundation	11.431	RF01148473		61,988
University of Michigan	11.432	3001071084		28,838
University of Michigan	11.432	3001262960		17,777
University of Michigan	11.432	3001332173		25,423
				138,753
Department of Commo	erce Subtotal			226,191
Department of Defense				
Direct Programs				
Other Department of Defense Programs	12.000			123,852
Basic and Applied Scientific Research	12.300			1,785,589
Military Medical Research and Development	12.420			1,477,741
Basic Scientific Research-ARRA	12.431 12.800			525,130
Air Force Defense Research Sciences Program-ARRA Research & Technology Development	12.800			805,623 1,153,089
Pass Through Programs	12.910			1,133,069
Advanced Technology Institute	12.000	2006-386		17,491
Giner, Inc.	12.000	W911NF-08-C0062		172,807
Timken Company	12.000	F33615-03-D-2353		(1,732)
Timken Company	12.000	TIMKEN		(7,665)
University of California, Berkeley	12.000	4714-10417		358,313
			-	539,214
Ohio Aerospace Institute	12.300	R-300-100197-10000		24,060
University of Washington	12.300	429159		85,508
				109,568
Ardiem Medical, Inc.	12.420	W81XWH0720044		285,930
Cleveland Clinic Foundation	12.420	W81XWH-07-1-0656		4,525
Rutgers University	12.420	S1072764		301,638
Henry M. Jackson Foundation-ARRA Princeton University-ARRA	12.800 12.800	680044 00001440		2,774 314,004
University of Utah	12.800	10013049		102,720
Oniversity of Otali	12.710	10013047		1,011,591
Department of Defe	ense Subtotal			7,531,397
Department of Housing and Urban Development				
Direct Programs				
General Research and Technology Activity	14.506			63,380
Healthy Homes Demonstration Grants	14.901			213,280
Pass Through Programs				
Ohio Department of Transportation	14.900			35,000

FEDERAL GRANTOR/PROGRAM TITLE	Catalog of Federal Domestic Assistance Number	Pass Through Entity Identifying Number	Expenditures
FEDERAL GRANTONI ROGRAM TITLE		Number	Expenditures
Department of Housing and Urban Development	Subtotal		311,660
Department of the Interior			
Direct Programs U.S. Geological Survey_Research and Data Collection	15.808		9,000
U.S. Geological Survey_Research and Data Confection	13.000		9,000
Department of the Interior	Subtotal		9,000
Department of Transportation			
Direct Programs			
Highway Planning and Construction-ARRA	20.205		47,309
Pass Through Programs University of Akron	20.701	DTRT06-G-0037	22 726
University of Akton	20.701	D1K100-G-003/	23,726
Department of Transportation	Subtotal		71,035
National Aeronautics and Space Administration			
Direct Programs Aerospace Education Services Program	43.001		835,353
Technology Transfer	43.002		448,309
Pass Through Programs			·
California Institute of Technology	43	44E-1083742	280,234
Ohio Aerospace Institute	43.001	WE-500077	193,102
University of Michigan	43.001	3001229609	40,840
National Space Biomedical Research Insti Universities Space Research Association	43.002 43.002	NPFR00206 04520-01	4,006 3,768
Virginia Commonwealth University	43.002	PT090702-SC100220	(2,827)
National Aeronautics and Space Administration	Subtotal		1,802,785
National Endowment for the Arts			
Pass Through Programs			
American Antiquarian Society	45.161		46,887
National Endowment for the Arts	Subtotal		46,887
National Science Foundation			
Direct Programs			
Engineering Grants	47.041		1,454,823
Mathematical & Physical Sciences	47.049		7,841,110
Geosciences	47.050		229,010
Computer and Information Science & Engineering Biological Sciences	47.070 47.074		996,839 940,431
Social, Behavioral and Economic Sciences	47.075		463,979
Education and Human Resources	47.076		414,503
Polar Programs	47.078		122,764
International Science and Engineering (OISE)	47.079		25,168
Trans-NSF Recovery Act Research Support-ARRA Pass Through Programs	47.082		1,309,689
Agiltron	47.041	NANOTRONS PO# 728458	44,403
Old Dominion University	47.041	09-133-383991	24,240
Scattering Solutions, LLC	47.041	IIP-0740033	8,165
University of Alabama	47.041	06-067	78,008
·			· ·
University of Illinois University of Iowa	47.041 47.041	2005-05374-03 420-17-77A	64,927 43,188

Environmental Protection Agency Pass Through Programs Buffalo State College 66.469 GL00E7530-CWR Environmental Protection Agency Subtotal Environmental Protection Agency Subtotal Department of Energy Direct Programs Other Department of Energy Programs Office of Science Financial Assistance Program-ARRA 81.049 Renewable Energy Research and Development-ARRA 81.087 Pass Through Programs 3M Company Advanced Technology Institute 81.000 LUSMIM040W3 Advanced Technology Institute 81.000 ATI 2005-301 Thomas Jefferson University 81.000 I00223371 University of Pittsburgh	(103) 46,553
Pass Through Programs Buffalo State College Environmental Protection Agency Subtotal Department of Energy Direct Programs Other Department of Energy Programs Office of Science Financial Assistance Program-ARRA Renewable Energy Research and Development-ARRA Pass Through Programs 3M Company Advanced Technology Institute Thomas Jefferson University University of Pittsburgh 66.469 GL00E7530-CWR 66.469 GL00E7530-CWR 61.000 GL00E7530-CWR 61.000 FILOUE7530-CWR 61.000 GL00E7530-CWR 61.000 GL00E7530-CWR 61.000 GL00E7530-CWR 61.000 GL00E7530-CWR	14,706,758
Buffalo State College Environmental Protection Agency Subtotal Department of Energy Direct Programs Other Department of Energy Programs Office of Science Financial Assistance Program-ARRA Renewable Energy Research and Development-ARRA Renewable Energy Research and Development-ARRA Pass Through Programs 3M Company Advanced Technology Institute Thomas Jefferson University University of Pittsburgh GL00E7530-CWR 66.469 GL00E7530-CWR 66.469 GL00E7530-CWR 61.000 41.000 GL00E7530-CWR	
Department of Energy Direct Programs Other Department of Energy Programs Office of Science Financial Assistance Program-ARRA Renewable Energy Research and Development-ARRA Ranewable Energy Research and Development-ARRA Pass Through Programs 3M Company Advanced Technology Institute Thomas Jefferson University University of Pittsburgh Environmental Protection Agency Subtotal 81.000 USMMM040W3 ATI 2005-301 100223371 University of Pittsburgh	9,993
Direct Programs Other Department of Energy Programs Office of Science Financial Assistance Program-ARRA Renewable Energy Research and Development-ARRA Ranewable Forgrams 3M Company Advanced Technology Institute Thomas Jefferson University University of Pittsburgh 81.000 USMMM040W3 At 1.000 ATI 2005-301 H133E070024	9,993
Direct Programs Other Department of Energy Programs Office of Science Financial Assistance Program-ARRA Renewable Energy Research and Development-ARRA Pass Through Programs 3M Company Advanced Technology Institute Thomas Jefferson University University of Pittsburgh 81.000 B1.000	9,993
Other Department of Energy Programs Office of Science Financial Assistance Program-ARRA Renewable Energy Research and Development-ARRA Rass Through Programs 3M Company Advanced Technology Institute Thomas Jefferson University University of Pittsburgh 81.000 Renewable Energy Research and Development-ARRA Renewable Energy Research and Development Energy Research Array R	
Office of Science Financial Assistance Program-ARRA Renewable Energy Research and Development-ARRA 81.087 Pass Through Programs 3M Company Advanced Technology Institute 81.000 Thomas Jefferson University University of Pittsburgh 81.000 H133E070024	(1,889)
Renewable Energy Research and Development-ARRA Pass Through Programs 3M Company Advanced Technology Institute Thomas Jefferson University University of Pittsburgh 81.000 ATI 2005-301 81.000 H133E070024	552,103
3M Company81.000USMMM040W3Advanced Technology Institute81.000ATI 2005-301Thomas Jefferson University81.000100223371University of Pittsburgh81.000H133E070024	601,920
Advanced Technology Institute 81.000 ATI 2005-301 Thomas Jefferson University 81.000 100223371 University of Pittsburgh 81.000 H133E070024	
Thomas Jefferson University University of Pittsburgh 81.000 100223371 81.000 H133E070024	269,191 48,067
University of Pittsburgh 81.000 H133E070024	5,628
Y 11 NY 1 1Y 1 1 1	85,729
Los Alamos National Laboratories 81.036 61008-001-08	21,441
Stanford University-ARRA 81.049 DE-FG02-05ER64136	45,914
BASF Fuel Cell, IncARRA 81.087 DE-PS36-07G097012	91,135
Bayer MaterialScience LLC-ARRA 81.087 DE-EE0001361 North American Die Casting Assoc-ARRA 81.117 DE-EE0001100	33,463 111,634
Univenture, IncARRA 81.135 DE-AR0000037	3,925
Department of Education	1,868,261
Department of Education Direct Programs	
Pass Through Programs	
Cincinnati Children's Hospital 84.133 107354	4,265
Brecksville-Broadview Heights Capa 84.184 BRECKSVILLE HTS.	(1,578)
Department of Education Subtotal	2,687
Department of Health & Human Services	
Direct Programs Food and Drug Administration Research 93.103	51,416
Food and Drug Administration_Research 93.103 Maternal & Child Health Federal Consolidated Programs 93.110	256,032
Environmental Health 93.113	480,982
Oral Diseases & Disorder Research 93.121	5,030,528
Centers for Research and Demonstration for Health Promotion and Disease Prevention 93.135	392,960
Human Genome Research Passage Palated to Desfrace & Communications Disorders 93.172	2,006,283
Research Related to Deafness & Communications Disorders 93.173 Immunization Research, Demonstration, Public Information and Education_Training and Clinical	1,279,959
Skills Improvement Projects 93.185	
Research and Training in Complementary and Alternative Medicine 93.213	331,845
Research on Healthcare Costs, Quality and Outcomes 93.226	331,845 527,238

EEDED AL CDANGOD (DDCCDANG TVIV)	Catalog of Federal Domestic Assistance	Pass Through Entity Identifying	
FEDERAL GRANTOR/PROGRAM TITLE	Number	Number	Expenditures
National Center on Sleep Disorders Research	93.233		1,532,926
Mental Health Research Grants	93.242		3,061,497
Occupational Safety and Health Program	93.262		53,024
Alcohol Research Programs	93.273		360,194
Drug Abuse and Addiction Research Programs	93.279		2,960,453
Mental Health Research Career/Scientist Development Awards	93.281		108
Centers for Disease Control and Prevention_Investigations and Technical Assistance	93.283		3,943,24
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286		5,372,644
Minority Health and Health Disparities Research	93.307		1,407,113
Trans-NIH Research Support	93.310		583,55
Nursing Research	93.361		2,172,513
National Center for Research Resources	93.389		13,419,980
Cancer Cause & Prevention Research	93.393		4,948,240
Cancer Detection and Diagnosis Research	93.394		2,366,859
Cancer Treatment Research	93.395		3,118,563
Cancer Biology Research	93.396		2,921,57
Cancer Centers Support Grants	93.397		4,259,722
Cancer Research Manpower	93.398		3,144,000
Cancer Control	93.399		148,913
Refugee and Entrant Assistance_Wilson/Fish Program	93.583		26,023
Trans-NIH Recovery Act Research Support-ARRA	93.701		14,705,493
Cardiovascular Diseases Research	93.837		11,426,06
Lung Diseases Research	93.838		2,731,886
Blood Diseases and Resources Research	93.839		2,065,74
Arthritis, Musculoskeletal, and Skin Diseases Research	93.846		4,876,072
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847		13,150,440
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853		8,811,708
Allergy, Immunology and Transplantation Research	93.855		15,353,160
Microbiology and Infectious Diseases Research	93.856		1,632,479
Biomedical Research and Research Training	93.859		7,393,960
Child Health and Human Development Extramural Research	93.865		4,647,228
Aging Research	93.866		7,153,928
Vision Research	93.867		8,088,463
Medical Library Assistance	93.879		394,753
Health Care and Other Facilities	93.887		913,34
International Research and Research Training	93.989		1,058,176
Pass Through Programs	02.000	T. A. C.T.	2.25
Mt. Sinai Health Care Foundation	93.000	TACT	3,360
Seattle Institute of Cardiac Research	93.000	HL067972	11,550
University of California, San Francisco	93.000	557445-25784	88,753
University of Florida	93.103	UF06127	51,76
Hemophilia Foundation of Michigan	93.110	6H30MC00015	14,05
Sensor Development Corporation	93.113	ES013664	6,62
Boston University	93.172	7426-5	36,64
Cornell University	93.173	56083-8774	126,24
Vanderbilt University	93.173	DC008408	(22,083
Vanderbilt University	93.173	VUMC32871-R	33,44
Baylor College of Medicine	93.184	100400918	17,37
Kent State University	93.213	443149-P0002692	53,08
University of Cincinnati	93.213	AT004454	115,79
Rush Presbyterian - St. Luke's Medical Center	93.226	HS015688	11,65
California Pacific Medical Center	93.233	2803209-S105	158,57
Washington University	93.233	WU-06-76	23,33
Cincinnati Children's Hospital	93.242	CHMC 102316 M3	266,76
Duke University	93.242	118685 SITE 14	66
Duke University	93.242	GCID#100528	16
Emory University	93.242	5-41045-G3	67,99
Neurotez, Inc.	93.242	NEUROTEZ	
Vanderbilt University	93.242	MH078028	230,337

	Catalog of Federal Domestic	Pass Through Entity	
FEDERAL GRANTOR/PROGRAM TITLE	Assistance Number	Identifying Number	Expenditures
The University of British Columbia	93.279	DA021525	105,645
Association of American Medical Colleges	93.283	U36/CCU319276	(3,150)
City of Cleveland	93.283	CITY OF CLEVELAND	175,148
Hemophilia Foundation of Michigan	93.283	U01/DD000203	11,996
Brown University	93.286	EB007401	24,655
Massachusetts Institute of Technology	93.286	5710002285	106,152
University of California, San Francisco	93.286	5365SC	43,632
University of the Virgin Islands	93.307	CALLWOOD-2008-1	22,644
Wake Forest University	93.361	WFUHS10104	7,676
Massachusetts Institute of Technology	93.389	5710001819	19,473
University of Alabama	93.389	RR025777	48,044
University of Mississippi	93.389	RR017701; 66208-CWRU	194,422
University of Utah	93.389	10006464-03	28,168
Massachusetts General Hospital	93.39	GM075946	3,160
Ohio State University Research Foundatio	93.39	60003197	30
American College of Radiology	93.393	CA021661	115
George Washington University	93.393	09-M33	73,566
Henry Ford Health System	93.393	CA112379	73,347
Huntsman Cancer Institute	93.393	10014775-01	1,390
Moffitt Cancer Center	93.393	10-14922-99-04-G5	11,819
National Childhood Cancer Foundation	93.393	19659	18,655
University of Minnesota	93.393	H001238301	795
University of South Carolina	93.393	PO:22060 SUB:10-1773	471
University of Texas- MD Anderson Cancer	93.393	28954/98012595	23,639
University of Texas- MD Anderson Cancer	93.393	CA139020	39,139
Virginia Commonwealth University	93.393	PD300205-SC101314	62,312
Virginia Commonwealth University BioInVision, Inc.	93.393 93.394	PT102388-SC101313	104,614
Burnham Institute	93.394 93.394	CA124270 CA071932	58,570 109,449
ContraDyn, Inc.	93.394	CA071932 CA128130	32,949
American College of Obstetricians & Gyne	93.395	27469-094	20,759
Medical University of South Carolina	93.395	MUSC07-030	23,240
National Childhood Cancer Foundation	93.395	18548	116,688
National Surgical Adjuvant Breast & Bowe	93.395	TFED39-#728	18,819
Ohio State University Research Foundatio	93.395	OHIO STATE UNIVER	68,689
Surfagen, Inc	93.395	CA135785	49,311
Univ. of Colorado Health Sciences Center	93.395	FY08.325.010	59,885
Wayne State University	93.395	WSU05014	51,009
National Surgical Adjuvant Breast & Bowe	93.399	PFED19-IRE-01	41,354
National Surgical Adjuvant Breast & Bowe	93.399	TIND-728	47,670
Southwest Oncology Group	93.399	CA037429	15,913
Scripps Research Institute	93.583	5-22770	(1,008)
Burnham Institute-ARRA	93.701	CA071932-12S2	26,287
California Pacific Medical Center-ARRA	93.701	2803261-S113	1,616
Cornell University-ARRA	93.701	60215-9032	100,000
Duke University-ARRA	93.701	165191	27,753
Duke University-ARRA	93.701	303-4985	115,176
Indiana University-ARRA	93.701	HL081819	74,512
Jaeb Center for Health Research- Contrac-ARRA	93.701	EY012358-11S1-CWRU	66,415
Johns Hopkins University-ARRA	93.701	2000784928	12,818
Johns Hopkins University-ARRA	93.701	2000879393	100,908
Medical College of Georgia-ARRA	93.701	23789-1	142,266
Medical College of Georgia-ARRA	93.701	DK076169	34,81
University of Massachusetts Boston-ARRA	93.701	10 005692 B 00	67,518
University of Medicine & Dentistry, NJ-ARRA	93.701	GM084039	45,278
University of Minnesota-ARRA	93.701	N001005501	17,74
University of North Carolina-ARRA	93.701	5-30249	138,092
University of Pennsylvania-ARRA	93.701	553520	51,533
University of Rochester-ARRA	93.701	1000015-D	29,437
Weill Medical College of Cornell University-ARRA	93.701	09111781	264,612
well Medical College of Collell University-ARRA	75.701	07111701	201,012

	Catalog of Federal Domestic Assistance	Pass Through Entity Identifying	
FEDERAL GRANTOR/PROGRAM TITLE	Number	Number	Expenditures
Brigham and Women Hospital	93.837	HL048743	466,90
Cleveland Clinic Foundation	93.837	U01 HL087314	68,43
Kent State University	93.837 93.837	443165-CWRU HL053353	28,60 20,69
Loyola University Chicago NIH-National Heart, Lung, and Blood Inst	93.837	HL092933	478,23
Northern California Institute for Resear	93.837	2 FRAM 767-01	(44,643
Northwestern University	93.837	PROJ0001040	40,65
St. Lukes's Roosevelt Institute for Heal	93.837	HL062509	6,42
University of California, Los Angeles	93.837	1568 G KB381	17,94
University of Maryland	93.837	SR00000925	442,30
University of Michigan	93.837	3001346374	42,74
University of Pittsburgh	93.837	115835-2	1,00
University of Pittsburgh	93.837	HL098177	14,59
University of Toledo	93.837	2008-007	11,44
Washington University	93.837	WU-09-186	10,09
The Broad Institute, Inc.	93.838	571002293-02	58,73
University of Chicago	93.838	37781	161,59
University of North Carolina	93.838	5-34400	217,41
University of North Carolina	93.838	5-51358	67,93
Cincinnati Children's Hospital	93.846	U01AR055054	1,58
Drexel University	93.846	232222-3850	97,58
Duke University	93.846	APPLE SITE 16	27,94
University of Rochester	93.846	5-29797	69,75
Cincinnati Children's Hospital	93.847	102243	34,46
Cleveland Clinic Foundation	93.847	PRELIMINARY	20,19
Department of Agriculture	93.847	5306-51530-019-17G	13,55
George Washington University	93.847	10-D02	573,96
George Washington University	93.847	DK061230	49
Medical College of Georgia	93.847	20497-21	21,06
Medical College of Georgia	93.847	23789-1	484,89
NIH-National Institute of Diabetes and D	93.847	DK42191	6,78
Thermalin Diabetes Incorporated	93.847	DK081292	40,59
University of Pittsburgh	93.847	0010021	13,27
University of Maryland	93.847	DK046461	92,49
University of Virginia	93.847	GC11314-134336	215,86
University of Virginia	93.847	GC11314-134338	343,30
Vanderbilt University	93.847	VUMC33829-R	18,42
Los Angeles Biomedical Research Institut	93.847	DK069844	77,41
University of Alabama, Birmingham	93.847	DK074038	26,88
University of California, San Francisco	93.847	4510SC	82,99
University of Chicago	93.847	TRACS:30004	37,55
University of Michigan	93.847	DK079912-01	12,79
University of Pennsylvania	93.847	5-44131	11,30
Wayne State University	93.847	WSU09056	3,10
Children's Hospital and Regional Medical	93.853	CHMC 380	23,19
Children's Hospital Research Foundation	93.853	CHMC #345	1,28
Medical University of South Carolina	93.853	MUSC08-063	3
The University of British Columbia	93.853	F09-04946	9,40
University of Alabama, Birmingham	93.853	NS042685-071	2,14
University of Cincinnati	93.853	COEUS 003525	16,63
University of Kentucky	93.853	NS066250	57,46
University of Kentucky	93.853	R01NS053470	
University of North Carolina	93.853	U01 NS042167	6,68
University of Texas Health Science Cente	93.853	122267-122182	67,32
University of Utah	93.853	10001299	111,95
Washington University	93.853	WU-10-332	53,68
Yale University School of Medicine	93.853	A07593	30,48
Iowa State University	93.855	430-23-12A	18,74
Iowa State University	93.855	AI074286	115,63
Johns Hopkins University	93.855	2000056544	47,66
<u>*</u>	93.855	4292	19,69

	Catalog of Federal Domestic Assistance	Pass Through Entity Identifying	
FEDERAL GRANTOR/PROGRAM TITLE	Number	Number	Expenditu
Magee Woman's Hospital	93.855	4339	57
Mount Sinai School of Medicine of the Ne	93.855	0255-1354-4609	240
Mount Sinai School of Medicine of the Ne	93.855	MT. SINAI	26
University of Alabama, Birmingham	93.855	AI067039	362
University of Iowa	93.855	AI74286	268
University of Maryland	93.855	SR00000593	2
University of South Florida	93.855	6408-1009-01-A	52
University of Texas Medical Branch	93.855	0007207A	23
University of Washington	93.855	R01 AI070090	22:
Washington University	93.855	WU-06-211	
Washington University	93.855	WU-10-292	12
Washington University	93.855	WU-10-302	46
Midwest Regional Center of Excellence	93.856	U54AI057160	
Oregon Health and Sciences University	93.856	GPEDI0184A1	3
Social & Scientific Systems, Inc.	93.856	BRS-ACURE-Q-06-00136	663
University of Wisconsin - Madision	93.856	292H143	84
University of Wisconsin - Madision	93.856	J033342	13′
Eli Lilly Pharmaceuticals Company	93.859	U54-GM074945-06	618
Mayo Foundation- Rochester	93.859	GM061388	15:
Structural Genomix Inc	93.859	SGX PHARMACEUTICALS	8
University of Chicago	93.859	41028-B	24
University of Michigan	93.859	3000949132	190
University of Pittsburgh	93.859	0002343	6
University of Illinois	93.864	492078 E5381	4:
Children's Research Institute	93.865	388509	207
Cincinnati Children's Hospital	93.865	106049	4
Duke University	93.865	DUKE UNIVERSITY	139
George Washington University	93.865	21050	260
Kent State University	93.865	445727-P070660	1′
Magee Woman's Hospital	93.865	26.635.653.3301.1370	(3
Ohio State University Research Foundatio	93.865	RF01076422/60012965	20
Ohio State University Research Foundatio	93.865	RF01152211	48
Pennsylvania State University	93.865	2253-CWRU-DHHS-8075	,
The Ohio State University	93.865	RF01194520	34
University of California, San Diego	93.865	10283438-002	193
University of Michigan	93.865	3000640016	
Aegis Biosciences LLC	93.866	AEGIS BIOSCI	3
Boston University	93.866	GC159610NGC	20
California Pacific Medical Center	93.866	2803212-S039	62
Duke Clinical Research Institute	93.866	159178	10
Rensselaer Polytechnic Institute	93.866	A12193	
Research Foundation for Mental Hygiene	93.866	24358	0
Rutgers University	93.866	3138	8:
University of California, San Diego	93.866	114 HBA	
University of California, San Diego	93.866 93.866	114NGF	20
University of California, San Diego Jaeb Center for Health Research	93.867	ADC-023 EY012358	33 72
Jaeb Center for Health Research- Contrac	93.867	DRCR - SITE 58	10
University of California, Irvine	93.867	10205850-009	33
University of Camorina, fivine University of Florida	93.867	UF06042	(3
University of Pennsylvania	93.867	552812	9:
University of Southern California	93.867	H44551	9.
University of Wisconsin - Madision	93.867	196044	522
West Virginia University	93.807	06-650-CWRU	21
Cuyahoga County Board of Health	93.944	CCBH	6
Department of Health & Human Services Subtotal			186,410
partment of Homeland Security			
Direct Programs			

	Catalog of Federal Domestic Assistance	Pass Through Entity Identifying	
FEDERAL GRANTOR/PROGRAM TITLE	Number	Number	Expenditures
Pass Through Programs University of Texas Medical Branch	97.061	10-045	12,310
Department of Homeland Security Subtotal			396,298
Total Research and Development - University Only			213,426,687
Research Training			
Department of Defense			
Direct Programs			
Basic and Applied Scientific Research	12.300		109,748
Military Medical Research and Development	12.420		205,009
Basic, Applied, and Advanced Research in Science and Engineering-ARRA	12.630		74,602
Department of Defense Subtotal			389,359
National Aeronautics and Space Administration			
Direct Programs			
Aerospace Education Services Program	43.001		67,289
Technology Transfer	43.002		5,624
National Aeronautics and Space Administration Subtotal			72,913
National Science Foundation			
Direct Programs			
Engineering Grants	47.041		123,042
Biological Sciences	47.074		23,685
Education and Human Resources	47.076		204,597
Trans-NSF Recovery Act Research Support-ARRA	47.082		116,767
Pass Through Programs			,,
Ohio State University Research Foundation	47.076	745922	17,413
Jackson State University	47.080	633108	14,250
	.,,,,,		- 1,-0
National Science Foundation Subtotal			499,754
Department of Education			
Direct Programs	0.4.200		500 504
Graduate Assistance in Areas of National Need	84.200		508,736
Special Education - Personnel Preparation to Improve Services and Results for Children with	04.225		20.425
Diabetes Page Through Programs	84.325		20,435
Pass Through Programs Cleveland State University	84.366	CI-667-OMAP-09-07	11,502
Department of Education Subtotal			540,673
Department of Health & Human Services Direct Programs			
Maternal and Child Health Federal Consolidated Programs	93.110		173,506
Oral Diseases & Disorder Research	93.121		60,839
Nurse Anesthetist Traineeships	93.124		16,382
National Research Service Awards_Health Services Research Training	93.225		293,032
National Center on Sleep Disorders Research	93.233		242,358
Mental Health Research Grants	93.242		150,372
Advanced Nursing Education Grant Program	93.273		37,520
Mental Health National Research Service Awards for Research Training	93.282		27,077

	Catalog of Federal Domestic Assistance	Pass Through Entity Identifying	
FEDERAL GRANTOR/PROGRAM TITLE	Number	Number	Expenditures
Discovery and Applied Research for Technological Innovations to Improve Human Health	93.286		395,078
Advanced Nursing Education Traineeships	93.358		141,558
Nursing Research	93.361		474,896
National Center for Research Resources	93.389		2,901,346
Cancer Biology Research	93.396		222,995
Cancer Research Manpower	93.398		2,037,335
Cancer Research Manpower-ARRA	93.407		18,896
Cancer Research Manpower-ARRA	93.701		220,370
Cardiovascular Diseases Research	93.837		408,093
Lung Diseases Research	93.838		726,569
Blood Diseases and Resources Research	93.839		193,713
Arthritis, Musculoskeletal and Skin Diseases Research	93.846		373,383
Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847		583,302
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.853		592,448
Allergy, Immunology and Transplantation Research	93.855		160,318
Microbiology and Infectious Diseases Research	93.856		7,626
Biomedical Research and Research Training	93.859		2,316,637
Child Health and Human Development Extramural Research	93.865		913,705
Aging Research	93.866		(2,943)
Vision Research	93.867		338,212
Grants for Training in Primary Care Medicine and Dentistry	93.884		582,780
Scholarships for Health Professions Students from Disadvantaged Backgrounds	93.925		43,093
Geriatric Education Centers	93.969		407,474
International Research and Research Training	93.989		1,203,227
Pass through programs			
Michigan State University	93.648	61-5101CWR	77,148
Research Foundation of State University	93.648	09-35	100,418
University of Georgia	93.989	RTW006900	54,317
Vanderbilt University	93.989	TW007988	53,413
Department of Health & Human Services Sub	ntatal		16 546 402
	notai		16,546,493
Total Research Training G			18,049,192
Total Research Training Goods Sub Total Research and Development and Research Training Cl	rants	Only	
Sub Total Research and Development and Research Training Cl Research and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services	rants	Only	18,049,192
Sub Total Research and Development and Research Training Cl Research and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs	rants luster - University (Only	18,049,192 231,475,879
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health	rants luster - University (93.113	Only	18,049,192 231,475,879 239,393
Sub Total Research and Development and Research Training Clesearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research	rants luster - University 93.113 93.121	Only	18,049,192 231,475,879 239,393 339,526
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research	93.113 93.121 93.172	Only	231,475,879 239,393 339,526 806,048
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research	93.113 93.121 93.172 93.173	Only	231,475,879 231,475,879 239,393 339,526 806,048 606,883
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine	93.113 93.121 93.172 93.173 93.213	Only	231,475,879 231,475,879 239,393 339,526 806,048 606,883 10,843
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training	93.113 93.121 93.172 93.173 93.213 93.272	Only	231,475,879 231,475,879 239,393 339,526 806,048 606,883 10,843 17,103
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs	93.113 93.121 93.172 93.173 93.213 93.272 93.273	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286 93.310	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286 93.310 93.389	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources Cancer Cause & Prevention Research	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286 93.310 93.389 93.393	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620 746,542
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources Cancer Cause & Prevention Research Cancer Detection and Diagnosis Research	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286 93.310 93.389 93.393 93.394	Only	18,049,192 231,475,879 239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620 746,542 537,135
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources Cancer Cause & Prevention Research Cancer Detection and Diagnosis Research Cancer Treatment Research	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286 93.310 93.389 93.393 93.394 93.395	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620 746,542 537,135 3,121,399
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources Cancer Cause & Prevention Research Cancer Detection and Diagnosis Research Cancer Treatment Research Cancer Biology Research	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286 93.310 93.389 93.393 93.394 93.395 93.396	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620 746,542 537,135 3,121,399 3,803,855
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources Cancer Cause & Prevention Research Cancer Detection and Diagnosis Research Cancer Treatment Research Cancer Biology Research Cancer Research Manpower	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286 93.310 93.389 93.393 93.394 93.395 93.396 93.398	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620 746,542 537,135 3,121,399
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources Cancer Cause & Prevention Research Cancer Detection and Diagnosis Research Cancer Treatment Research Cancer Biology Research Cancer Research Manpower Family Violence Prevention and Services/Grants for Battered Women's Shelters_Grants to Sta	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.273 93.286 93.310 93.389 93.393 93.394 93.395 93.396 93.398	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620 746,542 537,135 3,121,399 3,803,855
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources Cancer Cause & Prevention Research Cancer Detection and Diagnosis Research Cancer Treatment Research Cancer Research Manpower Family Violence Prevention and Services/Grants for Battered Women's Shelters_Grants to Sta and Indian Tribes	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286 93.310 93.389 93.393 93.394 93.395 93.396 93.398	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620 746,542 537,135 3,121,399 3,803,855
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources Cancer Cause & Prevention Research Cancer Detection and Diagnosis Research Cancer Treatment Research Cancer Research Manpower Family Violence Prevention and Services/Grants for Battered Women's Shelters_Grants to Sta and Indian Tribes Trans-NIH Recovery Act Research Support-ARRA	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.273 93.286 93.310 93.389 93.393 93.394 93.395 93.396 93.398	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620 746,542 537,135 3,121,399 3,803,855 1,596,855
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources Cancer Cause & Prevention Research Cancer Detection and Diagnosis Research Cancer Treatment Research Cancer Research Manpower Family Violence Prevention and Services/Grants for Battered Women's Shelters_Grants to Sta and Indian Tribes	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286 93.310 93.389 93.393 93.394 93.395 93.396 93.398 93.398	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620 746,542 537,135 3,121,399 3,803,855 1,596,855
Sub Total Research and Development and Research Training Classearch and Development - Cleveland Clinic Lerner College of Medicine (see Footnote 1) Department of Health & Human Services Direct Programs Environmental Health Oral Diseases & Disorder Research Human Genome Research Human Genome Research Research and Training in Complementary and Alternative Medicine Alcohol National Research Service Awards for Research Training Alcohol Research Programs Discovery and Applied Research for Technological Innovations to Improve Human Health Trans-NIH Research Support National Center for Research Resources Cancer Cause & Prevention Research Cancer Detection and Diagnosis Research Cancer Treatment Research Cancer Research Manpower Family Violence Prevention and Services/Grants for Battered Women's Shelters_Grants to Sta and Indian Tribes Trans-NIH Recovery Act Research Support-ARRA	93.113 93.121 93.172 93.173 93.213 93.272 93.273 93.286 93.310 93.389 93.394 93.395 93.396 93.396 93.398 sites	Only	239,393 339,526 806,048 606,883 10,843 17,103 1,720,295 86,114 174,760 877,620 746,542 537,135 3,121,399 3,803,855 1,596,855 59,143 5,503,906

FEDERAL GRANTOR/PROGRAM TITLE Arthritis, Musculoskeletal, & Skin Diseases Research Diabetes, Digestive, and Kidney Diseases Extramural Research Extramural Research Programs in the Neurosciences and Neurological Disorders Allergy, Immunology and Transplantation Research Biomedical Research and Research Training Child Health and Human Development Extramural Research Aging Research Vision Research Department of Health and Human Services Public Health Service Pass Through Programs University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC LAM Foundation	93.846 93.847 93.853 93.855 93.859 93.865 93.866	Number	Expenditures 1,744,702 6,967,029
Diabetes, Digestive, and Kidney Diseases Extramural Research Extramural Research Programs in the Neurosciences and Neurological Disorders Allergy, Immunology and Transplantation Research Biomedical Research and Research Training Child Health and Human Development Extramural Research Aging Research Vision Research Department of Health and Human Services Public Health Service Pass Through Programs University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.847 93.853 93.855 93.859 93.865 93.866		
Extramural Research Programs in the Neurosciences and Neurological Disorders Allergy, Immunology and Transplantation Research Biomedical Research and Research Training Child Health and Human Development Extramural Research Aging Research Vision Research Department of Health and Human Services Public Health Service Pass Through Programs University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.853 93.855 93.859 93.865 93.866		6,967,029
Allergy, Immunology and Transplantation Research Biomedical Research and Research Training Child Health and Human Development Extramural Research Aging Research Vision Research Department of Health and Human Services Public Health Service Pass Through Programs University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.855 93.859 93.865 93.866		
Biomedical Research and Research Training Child Health and Human Development Extramural Research Aging Research Vision Research Department of Health and Human Services Public Health Service Pass Through Programs University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.859 93.865 93.866		8,008,219
Child Health and Human Development Extramural Research Aging Research Vision Research Department of Health and Human Services Public Health Service Pass Through Programs University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.865 93.866		5,356,900
Aging Research Vision Research Department of Health and Human Services Public Health Service Pass Through Programs University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.866		3,005,918
Vision Research Department of Health and Human Services Public Health Service Pass Through Programs University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC			1,290,875
Pass Through Programs University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC			1,305,459
Pass Through Programs University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.867		1,811,486
University of Louisville Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.951		3,634
Mass Eye & Ear Infirmary Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC			
Massachusetts General Hospital Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.121	R21DE017706	3,015
Butler Hospital CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.173	U01 DC006296-01A1	(56)
CME Development Inc. Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.213	U01AT000613	4,760
Duke University Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.242	R01MH076179	64,133
Massachusetts General Hospital Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.242	R42MR073197	14,296
Biomedical Imaging/BIOENG Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.242	U10HL080413	8,465
Massachusetts General Hospital Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.242	R01MH071762	73,853
Source Signalt Imaging Inc. University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.286		881,507
University of California University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.286	R01EB009048	75,232
University of Southern Califorinia Boston University Cincinnati Children's Hospital RSC	93.286	R44EB000614	108
Boston University Cincinnati Children's Hospital RSC	93.286	R01EB008049	80,432
Cincinnati Children's Hospital RSC	93.286	R01EB002010	72,504
•	93.389	U54RR019497	12,564
I AM Foundation	93.389	R01AR050028	5,749
	93.389	U54RR019498	35,554
Bet Israel Deaconess Medical Center	93.393	R01CA95662	(9,474)
Dartmouth University	93.393	R01CA098286	191,006
Emory University	93.393	R01CA114456	(12,490)
Moffit Cancer CTR & RSCH	93.393	R01CA112112	6,957
University of Hawaii	93.393	R01CA104132	(18,073)
University of Southern California	93.393	U24CA074799	161,112
Brigham & Women's Hospital	93.394	R01CA100833	2,659
Cleveland BIOLABS	93.394	R44CA110885	(41,353)
Nanoprobes Inc.	93.394	R42CA083618	(15,519)
Ohio State University RSC	93.394	R01CA134451	13,875
Oncoscope Inc	93.394	R44CA128163	18,703
University of Washington at St. Louis	93.394	R01CA068124	58,926
University of Miami	93.394	R01CA122105	8,268
University of Nebraska	93.394	U01CA114778	42,372
University of Washington	93.394	R01CA107209	22,054
American College of Radio	93.395	U10CA021661	70,342
City of Hope	93.395	R01CA90559	16,494
Gynecological Oncology GR	93.395	U10CA027469	153,873
Johns Hopkins - Ongology	93.395	R01CA100904	3,060
Massachusetts General Hospital	93.395	P01CA084203	204,200
Moffit Cancer CTR & RSCH	93.395	R01CA131076	22,058
Ohio State University RSC	93.395	R01CA093871	(12,841)
Ohio State University RSC	93.395	U01CA044971	143,494
Southwestern Oncology Group	93.395	U10CA004919	41,383
University of Michigan	93.395	U10CA321022	9,512
University of Pittsburgh	93.395	P01CA109688	86,054
University of Pittsburgh	93.395	R01CA114071	51,379
Ohio State University RSC	93.396	P01CA097189	25,217
Ohio State University RSC	93.396	P01CA124570	364,560
Ohio State University RSC	93.397	U54CA113001	16,569
Biomedical Imaging/BIOENG	93.398	K08EB003468	7,435
City of Hope	93.399	R01CA096670	(4,068)
Dartmouth University	93.399		
Fred Hutchinson Center		R01CA059005	(27,299)
Meridia Cancer Institute	93.399	R01CA059005 R01CA0120582	(27,299) 3,086

	Catalog of Federal Domestic	Pass Through Entity	
FEDERAL GRANTOR/PROGRAM TITLE	Assistance Number	Identifying Number	Expenditures
University of California at Irving	93.399	U10CA037429	81,140
University of Colorado	93.399	R01CA068099	(2,498)
Beth Israel Deaconess Medical Center-ARRA	93.701	RC1CA146596Z	4,658
Biomedical Imaging/Bioengineering-ARRA	93.701	R03EB009651	34,483
May Clinic-ARRA	93.701	U01DK062410Z	59,212
Texas A&M-ARRA	93.701	R21HL093689	32,097
University of Cincinnati-ARRA	93.701	R01NS039512Z	10,213
University of Michigan-ARRA	93.701	RC2HL101740	8,632
University of Washington-ARRA	93.701	R01DK081368	83,495
University of Washington-ARRA	93.701	R01GM048085Z	70,66
Wake Forest University-ARRA	93.701	RC2HL101487	41,520
Washington University School of Med-ARRA	93.701	-	36,989
Biomec Cardiovascular Inc.	93.837	R44HL065815	87,547
Medstar Research Institute	93.837	U01HL064244	189,748
Mount Sinai School of Medicine	93.837	U01HL088942	126,651
Perfusion Solutions Inc.	93.837	R43HL096144	21,614
Pixel Velocity Inc.	93.837	R44HL071379	329
University of Washington at St. Louis	93.837	R01HL074283 P01HL070694	81,755
University of Connecticut	93.837 93.837	R01HL085487	32,187
University of Houston	93.837	R01HL075038	77,367
University of Pittsburgh University of Texas	93.837	U01HL087318	(120,968) 137,912
Duke University	93.838	Site 113	23,469
Duke University	93.838	U10HL080413	5,773
Tulane University Health SCI CT	93.838	U10 HL080510	37,269
University of Alabama at Birmingham	93.838	R01HL085324	29,196
University of Washington at St. Louis	93.838	R01HL091762	37,108
Vanderbilt University	93.838	R01HL083839	10,000
Biomec Cardiovascular Inc.	93.839	R44HL067483	(25,256)
Burke Medical Research Institute	93.839	R01HL082511	25,708
Nanomimetics, Inc.	93.839	R43HL082095	11,307
University of Washington at St. Louis	93.839	U01HL088476	28,639
University of Illinois	93.839	U54HL090513	232,011
Boston University	93.846	U54RR019497	157,710
Brigham & Woman's Hospital	93.846	R01AR055557	36,355
Cincinnati Children's Hospital RSC	93.846	P60AR047784	4,020
Cincinnati Children's Hospital RSC	93.846	R01AR049735	8,960
Seattle Children's Hospital	93.846	R01AR049762	46,359
Vanderbilt University	93.846	R01AR053684	9,281
Bertec	93.847	R44DK084844	4,035
Diapedia LLC	93.847	R44DK059074	12,889
Mayo Clinic	93.847	U01DK062410	78,751
Metrohealth Hospital	93.847	DK077668	99,882
Neurotron Inc.	93.847	R41DK074987	(22,554
Technest Inc.	93.847	R44DK071469	30,325
Vanderbilt University	93.847	U01DK072473	18,569
Feinstein Institute for M	93.847	R33DK070341	66,600
Loyola University Chicago	93.847	U01DK064044	(2,364
New England Medical CTR-T	93.847 93.847	K24DK078204 R01DK072231	1,472
University of Illinois University of Pennsylvania	93.847 93.847	U01DK060990	19,44 291,03
University of Pethisylvania University of Pittsburgh	93.847	R01DK070910	
Wayne State University	93.847 93.847	U01NS061264	(21,870 20,70
wayne State Oniversity Brigham & Women's Hospital	93.853	R01NS049639	(213
Cleveland Medical Devices	93.853	R42NS054348	95,01
Cleveland Medical Devices	93.853	R44NS042451	75,56
Cleveland Medical Devices	93.853	R44NS043816	45,00
Cleveland Medical Devices Cleveland Medical Devices	93.853	U44NS057969	101,81
Columbia University	93.853	R01NS047530	1,750
Columbia University	93.853	R01NS048212	178
Columbia University			

	Catalog of Federal Domestic Assistance	Pass Through Entity Identifying	
FEDERAL GRANTOR/PROGRAM TITLE	Number	Number	Expenditures
Cornell University	93.853	U01NS050324	17,338
Great Batch	93.853	R44NS039716	(26,298)
Massachusetts General Hospital	93.853	U01NS049640	66,584
Mayo Clinic	93.853	R01NS028492	255
Mayo Clinic Madical University of South Carolina	93.853 93.853	R01NS049577 U01NS058728	30,502 60,437
Medical University of South Carolina Mount Sinai School of Medicine	93.853 93.853	U01NS038728 U01NS045719	32,038
The Children's Hospital of PH	93.853	R01NS050488	5,521
Twin Star Medical Inc.	93.853	R43NS061364	9,517
University of California at L A	93.853	U01NS042372	1,029
University of California at San	93.853	R01NS062820	10
University of California at San	93.853	U01NS053998	351
University North Texas Health Science Center	93.853	R01NS048837	36,579
University of Cincinnati	93.853	R01NS039512	10,828
University of Iowa	93.853	R01NS040068	13,819
University of Iowa	93.853	R01NS054893	160,131
University of North Carolina Chapel Hill	93.853	5U01NS42167	48,572
Yale University	93.853	U01NS044876	(3,870)
University of Medicine & Dentist	93.853	R01NS038384	353
Brigham & Women's Hospital	93.855	U01AI063623	154,349
Cleveland BIOLABS	93.855	R01AI066497	(52,694)
Mount Sinai School of Medicine	93.855	U01AI063594	376,594
UCSF - SURGERY1	93.855	U01AI052748	61,840
University of Washington at St. Louis	93.855	U54AI057160	3
University of Washington at St. Louis	93.855	U01AI077810	36,443
University of Wisconsin-Madison	93.855	R01HL069116	200,572
University of Indiana	93.855	R01AI056318	1,726
University of Washington	93.855	R01AI083034	6,453
Vanderbilt University	93.855	R01AI065744	10,705
Wayne State University	93.855	R21AI064907	2,105
University of Michigan	93.865	U01HD041249	72,943
University of South Florida	93.865	U01DK061055	82,593
Mount Sinai School of Medicine	93.866	R01AG029656	45,974
Rutgers University @Brunswick	93.866	R01AG024494	45,897
University of Maryland Baltimore	93.866	R01AG016613	(1,935)
University of Colorado	93.866	P30AG015292	31,949
Arteriocyte Inc.	93.867	R41EY018784	492
Emory University	93.867	U10EY013272	3,654
Jackson Laboratories	93.867	R01EY016501	(236)
Jaeb Center Health Research	93.867	U10EY011751	1,653
Jaeb Center Health Research	93.867	U10EY012358	772
Medical College of Georgia	93.867	R01EY012830	24,774
University of Southern California	93.867	R01EY013516	54,787
Department of Health & Human Services Su	btotal		83,170,738
Total Research and Development - Cleveland Clinic Lerner Co.	llege of Medicine		83,170,738
Total Research and Development and Research Training Cluston	er		314,646,617
Student Financial Aid			
Department of Education Direct Programs Student Financial Aid Cluster			
Direct Programs-Student Financial Aid Cluster Federal Supplemental Educational Opportunity Grants	04.007		1.062.074
Federal Supplemental Educational Opportunity Grants	84.007		1,063,074
Federal Work-Study Program Federal Pell Grant Program	84.033 84.063		3,052,378 3,788,569
rederat ren Grant Frogram	84.003		7,904,021
Total Department of Education-SFA Cluster			7,904,021

	Catalo Feder Domes Assista	al Pass Ti	
FEDERAL GRANTOR/PROGRAM TITLE	Numb	er Nun	nber Expenditures
TRIO Department of Education Direct Programs			
TRIO_Upward Bound	84.04	.7	488,521
Department of Education Subtotal			488,521
	Total TRIO		488,521
Other Federal Assistance Department of Defense Direct Programs			
Military Medical Research and Development	12.42	00	20,000
Department of Def	ense Subtotal		20,000
Department of Transportation Direct Programs			
Highway Planning and Construction-ARRA	20.20	05	10,519
Department of Transporta	tion Subtotal		10,519
National Endowment for the Humanities			
Direct Programs Promotion of the Humanities_Professional Development	45.16		10,478
Tromotion of the Humanities_I folessional Development	45.10	3	10,478
National Endowment for the Human	ities Subtotal		10,478
Department of Veteran Affairs			
Direct Programs			
Other Department of Veteran's Affairs Programs	64.00	00	47
Department of Veteran Af	fairs Subtotal		47
Department of Education			
Direct Programs			
Other Department of Education Programs Pass through programs	84.00	00	822,300
Brecksville-Broadview Heights	84.18	44	32,585
Department of Educa	tion Subtotal		854,885
Department of Health & Human Services			
Direct Programs			
Research on Healthcare Costs, Quality and Outcomes Cardiovascular Diseases Research	93.22		1,194
Extramural Research Programs in the Neurosciences and Neurological Disorders	93.83 93.85		5,000 5,992
Aging Research	93.86		17,500
Health Care and Other Facilities	93.88		77,279
Ryan White HIV/AIDS Dental Reimbursements Community Based Dental Partnershi Block Grants for Community Mental Health Services	p 93.92 93.95		6,350 28,962
Pass Through Programs	93.90		20,902
YMCA of Greater Cleveland	93.28		7,376
Association of American Medical Colleges	93.28	3 5U36CD319276	4,211

FEDERAL GRANTOR/PROGRAM TITLE	Catalog of Federal Domestic Assistance Number	Pass Through Entity Identifying Number	Expenditures
Great Lakes Science Center	93.389	GLMSET	18
Booz Allen Hamilton, Inc.	93.393	79950CBS10	28,495
Booz Allen Hamilton, Inc.	93.393	79950CSB10	258
Children's Hospital and Regional Medical	93.846	413820230101	7,042
Scripps Research Institute	93.853	5-22770	(159)
University of Alabama	93.855	5R13AI1440-10	7,368
Social & Scientific Systems, Inc.	93.855	1 U01 AI068636-01	10,134
			64,743
Department of Health & Human Services S	ubtotal		207,020
Total Other Federal Ass	sistance		1,102,949
TOTAL EXPENDITURES OF FEDERAL AV	VARDS		\$ 324,142,108

1. Summary of Significant Accounting Policies

Basis of Presentation:

The accompanying Schedule of Expenditures of Federal Awards (the "Schedule") includes the federal grant transactions of Case Western Reserve University (the "University") recorded on the accrual basis of accounting. Because the Schedule presents only a selected portion of the operations of the University, it is not intended to and does not present the financial position, changes in net assets or cash flows of the University. Negative amounts represent adjustments or credits to amounts reported as expenditures in prior years. The information in this schedule is presented in accordance with the requirements of *OMB Circular A-133*, *Audits of States, Local Governments, and Non-Profit Organizations*.

In May 2002, the University entered into an agreement with the Cleveland Clinic Foundation ("CCF") to form a new medical education and research program, the Cleveland Clinic Lerner College of Medicine ("CCLCM"). This is a collaborative arrangement governed jointly by the University and CCF. The results of operations of the CCLCM are included in the University's accompanying financial statements. Beginning in fiscal 2004, research grants from the National Institutes of Health to support work by CCF-based investigators were awarded to and administered through the University by CCLCM, which operates as an academic unit of the University's School of Medicine.

Subrecipients:

Certain funds are passed through to subgrantee organizations by the University and CCLCM. Expenditures incurred by the subgrantees and reimbursed by the University are presented in the Schedule. Under the research and development program, a total of \$20,262,822 was passed through to subgranteed organizations from the University and \$7,237,731 from the CCLCM for the year ended June 30, 2010. \$97,328 was passed through under other programs.

2. Catalog of Federal Domestic Assistance Numbers:

Catalog of Federal Domestic Assistance ("CFDA") Numbers and Pass Through Entity Identifying Numbers are presented for those programs for which such numbers are available and were able to be identified by the University. The programs for which CFDA Numbers were not available or identified are reported with the federal agency's 2-digit prefix when known.

3. Facilities and Administrative Cost Rates:

The University recovers facilities and administrative costs by means of final facilities and administrative cost rates. The final rates are a result of negotiated agreements with the U.S. Department of Health and Human Services. The final rate effective for the period July 1, 2009 to June 30, 2010 for on-campus research and for the CCLCM is 57% of modified total direct costs. The base rates for off-campus research for the same period vary depending upon the location of the research.

4. Loan Advances:

The following schedule represents total loans advanced to students by the University and balances outstanding for the Perkins, Nursing, Health Profession Student and Disadvantaged Students Loan Programs for the year ended June 30, 2010:

	CFDA Number	Advances	C	Outstanding Balance
Perkins Loan Program	84.038	\$ 1,809,140	\$	17,537,328
Nursing Student Loan Program	93.364	5,750		301,557
Health Professional Student Loan Program/PCL	93.342	289,000		2,032,288
Loan for Disadvantaged Students	93.342	-		50,641

The Perkins Loan administrative cost allowance totalled \$0 for the year ended June 30, 2010.

5. Federal Family Education Loan Program

During the year ended June 30, 2010, the University disbursed the following loan amounts under the Federal Family Education Loan Program (FFELP) (which includes Stafford Loans, unsubsidized Stafford Loans, and Parents Plus Loans for Undergraduate Students):

	CFDA		
	Number		Amounts
Federal Family Education Loan Program	84.032	\$	102,816,128

6. Housing and Urban Development (HUD, CFDA #14.) Mortgage Bonds:

During the year ended June 30, 2010, the University made principal and interest payments of \$498,919 and \$900,562 respectively on HUD mortgage bonds and U.S. Government housing bonds. HUD mortgage bonds and U.S. Government housing bonds payable at June 30, 2010 amounted to \$18,203,370. See note 8 to the financial statements for further information concerning the components of these loans.

REPORTS ON COMPLIANCE AND ON THE INTERNAL CONTROL STRUCTURE



Report of Independent Auditors on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed In Accordance with Government Auditing Standards

To the Board of Trustees, Case Western Reserve University:

We have audited the consolidated financial statements of Case Western Reserve University and its affiliated entities, (the "University") as of and for the year ended June 30, 2010, and have issued our report thereon dated October 13, 2010. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States.

Internal Control Over Financial Reporting

In planning and performing our audit, we considered the University's internal control over financial reporting as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of the University's internal control over financial reporting.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis.

Our consideration of internal control over financial reporting was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over financial reporting that might be deficiencies, significant deficiencies, or material weaknesses. We did not identify any deficiencies in internal control over financial reporting that we consider to be material weaknesses, as defined above.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

This report is intended solely for the information and use of the University's Board of Trustees, management, federal awarding agencies and pass-through entities and is not intended to be and should not be used by anyone other than these specified parties.

October 13, 2010 Cleveland, Ohio

Pricewaterhouse Copers LAP

PricewaterhouseCoopers LLP, 200 Public Square, 18th Floor, Cleveland, OH 44114-2301 T: (216) 875 3000, F: (216) 566 7846, www.pwc.com/us



Report of Independent Auditors on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control over Compliance in Accordance with OMB Circular A-133

To the Board of Trustees, Case Western Reserve University:

We have audited the compliance of Case Western Reserve University (the "University") with the types of compliance requirements described in the OMB Circular A-133 Compliance Supplement that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2010 except as described in the second paragraph of this letter. The University's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs. Compliance with the requirements of laws, regulations, contracts and grants applicable to each of its major federal programs is the responsibility of the University's management. Our responsibility is to express an opinion on the University's compliance based on our audit.

We did not audit the University's compliance with the billing, cash receipts, due diligence and portfolio management compliance requirements specified by the Federal Perkins Loan Program and described in the OMB *Circular A-133 Compliance Supplement*. Compliance with these requirements was audited by other auditors whose report thereon has been furnished to us, and our opinion expressed herein, insofar as it relates to the University's compliance with those requirements, is based solely on the report of the other auditors.

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the University's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Our audit does not provide a legal determination of the University's compliance with those requirements.

In our opinion, based on our audit and the report of the other auditors, the University complied, in all material respects, with the requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2010. However, the results of our auditing procedures disclosed two instances of noncompliance with those requirements, which is required to be reported in accordance with OMB Circular A-133 and which is described in the accompanying schedule of findings and questioned costs as items 2010-1 and 2010-2.

Internal Control over Compliance

Management of the University is responsible for establishing and maintaining effective internal control over compliance with the requirements of laws, regulations, contracts, and grants applicable to federal programs. In planning and performing our audit, except as noted in the following paragraph, we considered the University's internal control over compliance with the requirements that could have a direct and material effect on a major federal program in order to determine the auditing procedures for the purpose of expressing our opinion on compliance and



to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly we do not express an opinion on the effectiveness of the University's internal control over compliance.

We did not consider internal control over compliance with the billing, cash receipts, due diligence and portfolio management compliance requirements specified by the Federal Perkins Loan Program and described in the OMB Circular A-133 *Compliance Supplement*. Internal control over these compliance requirements was considered by the other auditors referred to above; and our report, insofar as it relates to the University's internal control over those compliance requirements, is based solely upon the report of the other auditors.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect and correct noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that a material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected on a timely basis.


Our consideration and the other auditors' consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be deficiencies, significant deficiencies, or material weaknesses. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. Also, the report of the other auditors did not identify any deficiencies in internal control over compliance that they consider to be material weaknesses, as defined above.

The University's response to the findings identified in our audit is described in the accompanying schedule of findings and questioned costs. We did not audit the University's response and, accordingly, we express no opinion on the responses.

This report is intended solely for the information and use of management, the University's Board of Trustees, others within the entity, federal awarding agencies and pass-through entities and is not intended to be and should not be used by anyone other than these specified parties.

March 22, 2011 Cleveland, Ohio

Pricewaterhouse Copers LAP



For the year ended June 30, 2010

Section I – Summary of Auditor's Results

Financial Statements		
Type of auditor's report issued:		Unqualified
 Internal control over financial reporting: Material weakness(es) identified? Significant deficiency (s) identified that are n 	yes	X no
considered to be material weaknesses?	yes	\underline{X} none reported
Noncompliance material to financial statements noted?	yes	X no
Federal Awards		
 Internal control over major programs: Material weakness(es) identified? Significant deficiency(s) identified that are not 	yes	X no
considered to be material weaknesses?	yes	X none reported
Type of auditor's report issued on compliance for Any audit findings disclosed that are required to be		Unqualified
reported in accordance with section 510(a) of ON Circular A-133?	MB <u>X</u> yes	no
Identification of major programs: CFDA Number(s)	Name of Federal	Program or Cluster
Various	Research & Deve	lopment and Research
Various	Student Financial	Aid
Dollar threshold used to distinguish between		
type A and type B programs:	\$3,000,000	
Auditee qualified as low-risk auditee?	X ves	no

For the year ended June 30, 2010

Section II - Financial Statement Findings

No current year findings.

For the year ended June 30, 2010

Section III - Federal Award Findings and Questioned Costs

Finding #2010-1: Student Refunds

Student Financial Aid Cluster

Sponsoring Agency: Department of Education

CFDA #'s: 84.007, 84.003, 84.063

Award Year: FY2010

Information on the federal program/Condition/Context

Of the 60 students tested in the Student Financial Aid cluster we noted that 4 students had credit balances which were not processed in compliance with the required 14 day period.

Criteria or specific requirement

In accordance with 34 CFR 668.164(e), funds in excess of allowable institutional charges (i.e. credit balances) must be paid directly to the student or parent as soon as possible but no later than 14 days after the balance occurred if the credit balance occurred after the first day of class of a payment period; or no later than 14 days after the first day of class of a payment period if the credit balance occurred on or before the first day of class of that payment period.

Questioned Costs

None.

Cause/Effect

The University follows a policy of 14 business days for processing credit balances instead of 14 calendar days.

Recommendation

We recommend that the University update its policy to reflect 14 calendar days instead of 14 business days.

Views of responsible officials and planned corrective actions

Management's response is reported in the "Management's Views and Corrective Action Plan" and considered as part of this report.

For the year ended June 30, 2010

Finding #2010-2: Monitoring of CCLCM Award Activity

Research and Development Cluster

Sponsoring Agency: Department of Health and Human Services

CFDA #'s: Various - CCLCM Awards

Award Year: FY2010

Information on the Federal Program/Condition/Context

For the research grants that are awarded through Cleveland Clinic Lerner College of Medicine of Case Western Reserve University ("CCLCM") and administered by Cleveland Clinic Foundation ("CCF"), the University utilizes the CCF A-133 report as the primary means of monitoring how CCF complies with the various federal compliance requirements of research and development awards. However, as CCF reports on a December 31st year end and the University is on a June 30th fiscal year end, there is a six month lag in A-133 reporting and, therefore, in what is available for the University to review. In addition, although the operations of CCLCM are overseen jointly by the University and CCF many of the post-award administrative functions are performed only by CCF in accordance with an affiliation agreement and jointly designed operating procedures. The University does not routinely perform detailed monitoring procedures of the day-to-day monitoring performed by CCF on behalf of CCLCM. For instance, cash draw-downs are performed by CCF using CCLCM drawdown accounts and federal status reports are signed by a CCF official on behalf of CCLCM; however, the University does not perform a detailed review of the support behind these drawdowns or reports which are compiled by CCF employees on behalf of CCLCM.

Criteria or specific requirement

As required by OMB Circular A-110, Subpart C. Reports and Record, section 51 (a), the University is responsible for managing and monitoring each project, program, subaward, function or activity supported by the award.

Questioned Costs

None.

Cause/Effect

Significant reliance is placed on the affiliation agreement which covers the arrangement and operating procedures between CCLCM and the University. The affiliation agreement, which has been in place since the inception of the joint program with CCF, was discussed with the National Institute of Health ("NIH") at the inception of this affiliation.

These specific awards are in the name of the Case Western Reserve University or CCLCM and, therefore, the University is the prime recipient. As the prime recipient, the University is required to monitor the activity of all subrecipients within the guidance developed by OMB. As such, the University may not be performing sufficient monitoring of activities of CCF on behalf of CCLCM.

For the year ended June 30, 2010

Recommendation

We recommend that the University enhance its monitoring of CCF compliance activities associated with CCLCM awards by performing monitoring activities at a more detailed level along with the higher level governance oversight currently in place. Such detailed monitoring activities could include among other activity, a periodic review of CCLCM documentation to support draw-downs and requisite cash management procedures performed by CCF and related financial status reports prepared by CCF on behalf of CCLCM.

Views of responsible officials and planned corrective actions

Management's response is reported in the "Management's Views and Corrective Action Plan" and considered as part of this report.

For the year ended June 30, 2009

Summary of Prior Year Findings and Questioned Costs

No prior year findings.



Management's Corrective Action Plan

Finding #2010-1: Student Refunds

Management's Response:

The University agrees with this finding. The University has updated its policy to ensure that funds in excess of allowable institutional charges are processed in accordance with the criteria above within 14 days.

Responsible area: Director, Financial Aid

Finding #2010-2: Monitoring of CCLCM Award Activity

Management's Response:

Effective March 2011, management has instituted enhanced monitoring procedures which will be effective with the audit period ending June 30, 2011. The new procedures will include review of CCLCM's Letter of Credit (LOC) process and random periodic sampling of the LOC drawdowns and review of the Federal Financial Reports (FFR).

Responsible area: Assistant Vice President for Research

Signed:

Bradley W. Fralic University Controller